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ABSTRACT OF THE DISSERTATION 
MULTIMODAL	IMAGING FOR ENHANCED DIAGNOSIS AND FOR ASSESSING 
PROGRESSION OF ALZHEIMER’S DISEASE 
by 
Chunfei Li 
Florida International University, 2018 
Miami, Florida 
Professor Malek Adjouadi, Major Professor 
A neuroimaging feature extraction model is designed to extract region-based image 
features whose values are predicted by base learners trained on raw neuroimaging 
morphological variables. The main objectives are to identify Alzheimer’s disease (AD) in 
its earliest manifestations, and be able to predict and gauge progression of the disease 
through the stages of mild cognitive impairment (EMCI), late MCI (LMCI) and AD. The 
model was evaluated on the ADNI database and showed 75.3% accuracy for the 
challenging EMCI diagnosis based on the 10-fold cross validation. Our approach also 
performed well for the other binary classifications: EMCI vs. LMCI (72.3%), EMCI vs. 
AD (95.0%), LMCI vs. AD (84.3%), CN vs. LMCI (77.5%), and CN vs. AD (96.5%). By 
applying the model to the Genome-wide Association Study, along with the sparse Partial 
Least Squares regression method, we successfully detected risk genes such as the APOE, 
TOMM40, RVRL2 and APOC1 along with the new finding of rs917100. 
Moreover, the research aimed to investigate the relationship of different biomarkers; 
especially the imaging biomarkers to better understand the precise biologic changes that 
 vi 
characterize Alzheimer’s disease. The unique and independent contribution of APOE4 
allele status (E4+\E4-), amyloid (Aβ) load status (Amy+\Amy-) and combined APOE4 
and Aβ status on regional cortical thickness (CTh) and cognition were evaluated via a 
series of two-way ANCOVAs with post-hoc Tukey HSD tests. Results showed that 
decreased CTh is independently associated with Amy+ status in many brain regions, but 
with E4+ status in very restricted number of brain regions. Among CN and EMCI 
participants, E4+ status is associated with increased CTh, in medial and inferior temporal 
regions. 
Diverging association patterns of global and regional Aβ load with cortical volume were 
found in the entorhinal, temporal pole and parahippocampal regions, which were 
positively associated with regional Aβ load, but with a negative correlation for global Aβ 
load in MCI stages.  
In addition, strong positive correlations were shown between baseline regional CTh and 
the difference of CTh in each region between the CN and AD, even after adjusting for the 
regional Aβ and APOE genotype (E4+: r = 0.521 and E4-: r = 0.694). 
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 1 
INTRODUCTION 
 
Alzheimer’s disease is a neurodegenerative disorder characterized by the progressive loss 
of neural cells, affecting parts of the brain that control thought, memory, and sometimes 
language. In 2011, the National Institute on Aging (NIA) and the Alzheimer’s 
Association proposed revised criteria and guidelines for diagnosing Alzheimer’s disease, 
and three stages of Alzheimer’s disease were identified: preclinical Alzheimer’s disease, 
mild cognitive impairment (MCI) due to Alzheimer’s disease, and dementia due to 
Alzheimer’s disease (AD) [1-4]. In the preclinical Alzheimer’s disease stage, individuals 
have not yet developed noticeable symptoms such as memory loss, but do have some 
noticeable changes in the brain. In the MCI stage, which is subdivided into early MCI 
(EMCI) and late MCI (LMCI) by the Alzheimer’s disease Neuroimaging Initiative 
(ADNI), people have mild symptoms in thinking abilities but can still perform everyday 
tasks. Studies show that about 10–12% of subjects with MCI progress to AD per year [5]. 
However, MCI does not always lead to dementia. In some individuals, MCI reverts to 
normal cognition or remains stable. The AD stage is characterized by quite noticeable 
memory, thinking and behavioral symptoms that impair a person’s ability to function in 
daily life.  
As the population of the United States ages, Alzheimer’s is becoming a more common 
cause of death. According to data from the National Center for Health Statistics of the 
Centers for Disease Control and Prevention (CDC), between 2000 and 2013, deaths 
attributed to Alzheimer’s disease increased 71 percent, while those attributed to other 
major causes (breast cancer, prostate cancer, heart disease, stroke, and HIV, etc.) have 
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decreased significantly [6]. In 2013, 84,767 people died from AD, and an estimated 
700,000 people in the United States age 65 and older will die with AD based on the 
Chicago Health and Aging Project (CHAP) [7]. Due to the aging of the population and 
with more people living longer, the number of individuals with Alzheimer’s disease is 
projected to double by 2050. Thus, early and reliable detection is believed to be the key 
to preventing, slowing and potentially stopping Alzheimer’s disease. 
Alzheimer’s disease (AD) is associated with the excessive aggregation of amyloid beta 
protein (Aβ) outside neurons and tau protein inside nerve cells. Neuropathological 
diagnostic criteria for AD [8] require the deposition of Aβ, which accumulates initially 
and most prominently in neocortical regions, such as the precuneus, posterior and anterior 
cingulate gyrus, and the orbitofrontal cortex, and tau-associated neurofibrillary tangles [9, 
10]. Neurofibrillary tangle pathology in AD, in contrast to Aβ-associated pathology, 
follows a stereotypical topographic pattern initially involving the most selectively 
vulnerable regions, such as the entorhinal cortex (ERC) and parahippocampal gyrus, and 
then progressing to limbic and finally association cortices [11]. 
According to the amyloid hypothesis [8], deposition of amyloid beta protein (Aβ) in the 
neocortex, is the initiating event in the pathophysiology of Alzheimer’s disease (AD) and 
occurs 15 to 20 years before the first symptoms of the disease. This leads to downstream 
events including neurodegeneration and ultimately cognitive and functional impairment. 
Recent neuropathological diagnostic criteria for AD are based upon this hypothesis, 
incorporating the Thal phase schema of a stereotypic pattern of Aβ accumulation, 
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anteceding Braak staging of neurofibrillary tangle pathology in the brain, with a 
continuous relationship existing between brain Aβ load and neurodegenerative changes 
[9]. 
Another insight into the AD can be gained by exploring its genetic foundation. The 
single-nucleotide polymorphism (SNP), which is the most common and stable type of the 
DNA sequence variations, has commonly been used to analyze and identify complex 
neurological diseases such as AD. So far, the apolipoprotein E (APOE) gene is one of the 
prevalent risk factor that has been shown to have a strong connection with AD. More 
precisely, among its three variants alleles, APOE e2, APOE e3, and APOE e4 (APOE4), 
APOE4 is found to be the one most associated with increased risk for AD [12-17]. Some 
other genes such as TOMM40 [18, 19], CLU [20] and PVRL2 [21] are also considered to 
be significant risk factors. 
There is also considerable evidence that APOE E4 (APOE4) carrier (E4+) status is 
associated with greater Aβ load in normal individuals as well as in all stages of AD, 
possibly as a result of the effect of APOE4 genotype on impaired clearance of Aβ protein 
[22, 23]. Aging and E4+ status are among the most strongly associated factors with 
increased risk for AD [22-24]. Recent clinical criteria for the diagnosis of AD dementia 
and Prodromal AD (NIA-AA and IWG criteria) rely on combinations of “positive 
biomarkers” in the presence of functional and/or cognitive impairment with high, 
intermediate or low levels of likelihood [2, 25] based on the presence of Aβ and 
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neurodegenerative biomarkers. The presence of Aβ biomarkers in the absence of 
cognitive and functional impairment fulfills criteria for a diagnosis of preclinical AD.  
Neuroimaging is an important research platform for understanding the complicated 
pathogenesis of Alzheimer’s disease (AD). Deposition of Aβ in vivo is detectable with 
positron emission tomography (AV45 PET) scans, using an Aβ binding ligand, or by 
measuring Aβ levels in the cerebrospinal fluid (CSF), whereas downstream events such 
as neurodegeneration are detectable using volumetric measures of regional atrophy 
(especially hippocampal atrophy) and reduced cortical thickness (CTh) on structural 
magnetic resonance imaging (MRI) scans, as well as deficits in regional cerebral glucose 
metabolism on PET scans (FDG PET). Compared with the MRI, the cost of PET scans is 
extremely high; hence not every subject underwent all types of the PET, such as the 
AV45 and FDG PET.  
In recent years, machine learning and deep learning techniques have been widely 
performed in the diagnosis of Alzheimer's Disease (AD), and its prodromal stage, mild 
cognitive impairment (MCI), and reached very high diagnostic accuracy. It is believed 
that, combinations of different biomarkers could improve the classification performance. 
However, this will lead one of the main challenges in the area of imaging-based 
diagnosis, which is the extremely high dimensionality of image data (hundreds of 
morphological variables or millions of voxels), albeit with a relatively small number of 
subjects in AD research (few hundreds). To reduce the feature dimensions, some 
researchers proposed features selection pipeline such as pre-selecting brains regions 
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sensitive to AD (e.g. entorhinal cortex, parahippocampal gyrus, and hippocampus), or 
ranking features with regrads to their discrimicate significant difference between CN and 
AD/MCI [26-31]. Alternatively, others performed feature extraction frameworks to map 
the original high dime to the lower new space. Such methods include principle 
component analysis (PCA), linear discriminant analysis, and Independent Component 
Analysis (ICV) [32-36]. Recently, deep learning techniques are widely used in the AD 
classification at the voxel level with the hypothesis that predefined regions could 
potentially downgrade the power of the biomarker to detect differences or changes over 
time[35, 37-45]. However, only few studies have mentioned the performance on the 
diagnosis of EMCI so far [31, 35, 38, 39, 43, 46]. 
On the other hand, although it is well accepted that Aβ load, APOE4 status and 
neurodegeneration are strongly interrelated [47], the presence and strength of the 
relationships between these factors and their independent effects on cortical thinning and 
cognition are not well understood at different stages of disease. As emerging treatments 
are developed, it is increasingly important to understand these independent relationships 
prior to developing appropriate disease modifying treatments for AD.     
In this dissertation, we aim to early identify Alzheimer’s disease, and predict the 
progression in MCI and AD by incorporating imaging and any other biomarkers, results 
of cognitive tests and patient’s medical history in the most effective way with the 
hypothesis that combinations of different biomarkers could improve the classification 
performance. Also, the research aims to investigate the relationship of different 
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biomarkers, especially the imaging biomarkers to better understand the precise biologic 
changes that cause Alzheimer’s disease, which helps to developing appropriate disease 
modifying treatments for AD. 
Specifically, the performance of the AV45 PET and the FDG PET on the diagnosis of the 
different stages was first investigated in Chapter 1. And the one with better performance 
in the early stage of AD was selected and used in the following studies. In Chapter 2, we 
proposed a region-based neuroimaging extraction model to assist the diagnosis of the AD 
and its prodromal stage. The proposed feature extraction model was also used in the 
Genome-wide Association Study of Alzheimer’s Disease as explained in Chapter 3. 
Regarding the relationship of different imaging biomarkers, the association of different 
types of imaging biomarkers, APOE4 gene and the cognitive performance were 
thoroughly studied Chapter 4; the association patterns of regional cortical atrophy with 
global and with regional amyloid deposition in the progression of AD were explored in 
Chapter 5 and Chapter 6. Finally, the relationships between the baseline regional cortical 
thickness, baseline regional amyloid load and selective vulnerability to atrophy is 
examined in Chapter 7. 
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CHAPTER I 
 INVESTIGATING THE UTILITY OF FDG-PET AND AV45-PET IN 
CLASSIFICATION OF ALZHEIMER’S DISEASE AND ITS PRODROMAL 
STAGES 
1.1. Goal 
This study is aimed to explore the independent and interactive effects of the two 
commonly used 18F amyloid radiotracers (AV45 and FDG) on discriminating Alzheimer 
Disease (AD), early and late mild cognitive impairment (EMCI and LMCI) from 
cognitive normal (CN). It’s also aimed to examine the diagnostic power of the two PET 
radiotracers based on binary classification and multi-classification methods. 
1.2. Materials and Methods 
1.2.1. Data  
Data used in the preparation of this article were obtained from the ADNI database 
(adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led 
by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been 
to test whether serial magnetic resonance imaging (MRI), positron emission tomography 
(PET), other biological markers, and clinical and neuropsychological assessment can be 
combined to measure the progression of mild cognitive impairment (MCI) and early 
Alzheimer’s disease (AD).  
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For this first study, 508 subjects (CN (135), EMCI (208), LMCI (208), or AD (102)) 
underwent both 18F-AV45 Amyloid PET scan and 18F-FDG PET scan were included in 
this study. The Baseline demographic information was shown as shown in Table 1. 
Table 1. Participant demographic information 
 CN EMCI LMCI AD p-valueb 
Number of Subjects (n) 135 208 102 63 N/A 
Gender (Male/Female) 65/70 112/96 54/48 36/27 0.632 
Age (Years) 73.7(6.0)a 70.0(6.9) 71.2(7.8) 75.1(8.0) < 0.0001 
Education (Years) 16.4(2.5) 16.0(2.7) 16.5(2.7) 15.9(2.5) 0.291 
a Unless otherwise noted, data presented as mean (standard deviation). 
b The p values of ANOVA testing between the four groups were shown, and age is found to be a 
significant factor. 
 
1.2.2. PET Analysis 
A detailed description of PET protocols and acquisition procedures can be found in the 
following link: http://adni.loni.usc.edu/methods/pet-analysis/pre-processing. Briefly, all 
PET images were acquired 30 to 60 minutes post-injection, co-registered, averaged, 
reoriented into a standard 160×160×96 voxel image grid, and smoothed to a uniform 
isotropic resolution of 8 mm full width of maximum. 18F-FDG: Normalized intensity of 
the five pre-defined regions of interest (MetaROIs) – Post Cingulate Gyrus, Left Angular 
Gyrus, Right Angular Gyrus, Left Temporal Gyrus and Right Temporal Gyrus - as well 
as a composite region made up of all five regions were used as the 6 classification 
features. 18F-AV45: Mean standardized uptake value ratios (SUVRs) for four cortical 
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regions (frontal, anterior/posterior cingulate, lateral parietal, and lateral temporal) and 
three reference regions (cerebellar grey matter, whole cerebellum, and brainstem/pons) 
were used as the additional 7 classification features (Fig. 1). 
 
Fig. 1. The five individual MetaROI used in 18F-FDG. 
1.2.3. Investigation of FDG, AV45 and Their Interactive Effect   
Two multiple linear regression models – additive and non-additive were performed to 
determine the contribution of each radiotracer and identify if there is a significant 
interaction between them. The difference of the two models is that the additive model 
assumes independence of two biomarkers, while non-additive model considers the 
interaction of the two as well. The features used in this step were the average FDG-PET 
for 5 MetaROIs and the average AV45 SUVR for the 4 aforementioned ROIs. 
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1.2.4. Classification Experiment 
Support vector machine (SVM) classifier with a kernel of Gaussian radial basis function 
was applied to FDG and AV45 data separately and combined. The experiment is 
designed for both two-classification and multi-classification with 10-fold cross-
validation. 
1.3. Results 
The results of investigating the interactive effect of the two biomarkers are shown in 
Table 2, which shows that in the additive model, both biomarkers are significant. 
However, in the non-additive model, FDG, when taken out of the interactive effect with 
AV45, is no longer significant. As expected, the interaction of the two biomarkers in the 
non-additive model are significant. 
Table 2. P-values of multiple linear regression models 
PET radiotracers Non- additive model Additive model 
lm(DX ~ AV45_bl + FDG_bl+ AV45_bl: FDG_bl) lm(DX ~ AV45_bl + FDG_bl) 
AV45 < 0.001 < 0.001 
FDG 0.105 < 0.001 
Interaction < 0.001 N/A 
 
As can be seen from the results given in Table 3, FDG outperforms AV45 in most of the 
compared two-classification cases except for CN vs. LMCI and CN vs. EMCI. It may be 
deduced that FDG is more capable of capturing patterns of AD, while biomarker AV45 
detects patterns of prodromal stage of AD more efficiently. It also shows that combining 
both biomarkers doesn’t have a significant increase in accuracy when compared with the 
 11 
results using either of them. In particular, while discriminating AD from CN, FDG 
biomarker alone achieved 90.11% accuracy, and this accuracy increased to 92.67% when 
using both biomarkers. Multi-classification proved more challenging, and the results 
suggest that combining the two biomarkers still achieves a higher performance. 
It may be inferred from the results in Tables 2 and 3 that even as FDG displays much 
higher discriminative efficiency between AD and CN, however, when taking out the 
interaction effect of the two biomarker, FDG may not be able to discriminate EMCI 
and/or LMCI from CN anymore, and is somewhat inconsequential in the non-additive 
model as shown in Table 2. 
Table 3.  Accuracy of SVM using 10-fold cross validation (%) 
 AV45 FDG AV45 and FDG 
Two-group Classification    
CN vs. AD 83.59 
 
90.11 
 
92.67 
 
CN vs. LMCI 74.42 
 
71.47 
 
75.44 
 
CN vs. EMCI 65.09 
 
61.17 
 
62.99 
 
EMCI vs. AD 81.16 
 
88.23 
 
87.08 
 
EMCI vs. LMCI 68.06 
 
70.32 
 
70.65 
 
LMCI vs. AD 62.39 
 
73.93 
 
74.45 
 
Multi-group Classification 
 
 
   
CN vs. EMCI vs. LMCI vs. AD 45.64 
 
48.06 
 
50.4 
  
 
1.4. Conclusion 
This study, by establishing two multiple linear regression models (additive and non-
additive), confirmed previous findings that the two biomarkers (AV45 and FDG) are 
highly correlated with respect to the diagnosis. The results also indicate that AV45 
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outperforms FDG in case of EMCI vs. CN and LMCI vs. CN, while FDG is more 
effective than AV45 in separating AD from CN as well as from its prodromal stages - 
EMCI and LMCI. When using both the two-group and multi-group classifications, 
combining FDG and AV45 slightly improves the classification accuracy.  
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CHAPTER II  
ENHANCED REGION-BASED NEUTOIMAGING FEATURES FOR THE 
EARLY DETECTION OF ALZHEIMER’S DISEASE 
2.1. Goal 
In this study, we present a region-based neuroimaging biomarker extraction model based 
on shape and functional features from MRI and PET imaging to fuse the information 
associated with the disease, i.e. the probability of being EMCI. The extracted biomarkers 
along with patients’ demographic information such as age, gender and APOE status are 
used as the predictors in the EMCI classification model. The proposed framework was 
also evaluated on the other binary classification tasks: CN vs. LMCI, CN vs. AD, EMCI 
vs. LMCI, EMCI vs. AD, and LMCI vs. AD. 
2.2. Materials and Method 
2.2.1. Data 
For this second study, 893 subjects who underwent MRI and their first AV45 PET scans 
within 6 months and with available APOE gene information were involved in this study. 
They were categorized into groups of CN (247), EMCI (295), LMCI (193) and AD (158) 
according to ADNI diagnosis criteria, which assessed individual’s Mini-Mental State 
Examination (MMSE) score, Clinical Dementia Rating (CDR) score and education 
adjusted score on delayed paragraph recall from Wechsler Memory Scale Logical 
Memory II. Table 4 provides the demographics of the study subjects. 
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Table 4. Participants’ demographic information 
 CN EMCI LMCI AD  F-valuea P-Value 
N 247 295 193 158   
Female/Male 125/122 131/164 83/110 67/91 3.84 0.280 
APOE4 0/1/2 180/61/6 168/109/18 92/75/26 52/74/32 85.2 <0.001 
Age (year) 75.3(6.5)b 71.3(7.4) 73.6(8.1) 74.7(7.8) 14.72 <0.001 
Education (year) 16.4(2.6) 16(2.7) 16.3(2.7) 15.8(2.7) 2.4 0.067 
MMSE 29(1.2) 28.3(1.6) 27.6(1.9) 22.8(2.7) 433.1 <0.001 
a F-values are for ANOVA test (continuous attribute: Age, Education, and MMSE) or Chi-square test 
( categorical attribute: gender and APOE genotype), significance level is 0.05 by default 
 
b Values are represented as mean(standard deviation) for all continuous attributes 
 
 
2.2.2. Neuroimaging Acquisition 
In terms of MRI scans, the MPRAGE files as used in our study had undergone the 
following correction steps: (i) Gradwarp: corrected image geometry distortion due to 
gradient non-linearity (for MRI obtained by GE and Siemens systems only); (ii) B1 
correction: employed the B1 calibration scans to correct the image intensity non-
uniformity (for GE and Siemens systems with receive-only head RF coils only); and (iii) 
N3: applied the N3, a histogram peak sharpening algorithm, to 3T MRI (ADNI 1/GO/2) 
to reduce intensity non-uniformity due to the wave or the dielectric effect and 1.5T MRI 
(ADNI 1) to reduce residual intensity non-uniformity (for Phillips Systems and GE and 
Siemens systems). The resulting pre-processed MRIs were labeled with “N3” in ADNI.  
Each subject’s first AV45 PET scan was selected along with the structural MRI that was 
closest in time to PET acquisition. Details of AV45 PET and MRI imaging acquisition 
and pre-processing steps can be found in the aforementioned ADNI website. In brief, the 
ADNI had already performed the attenuation correction for all PET scans. And the PET 
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image was then preprocessed following these specific steps: (i) co-registered the 
extracted 5 five-minute frames to the first extracted frame from raw PET to lessen the 
effects of patient motion; (ii) averaged the co-registered dynamic 6 frames to create a 
single 30 min PET image; (iii) reoriented the 30 min PET to a standard 160x160x96 
voxel image grid with 1.5 mm cube voxels and normalized the intensity of the PET scan; 
and (iv) smoothed the above image with a scanner-specific filter, and obtained our pre-
processed PET scan of a uniform isotropic resolution of 8 mm Full Width at Half 
maximum (FWHM), which was identified with “AV45 Coreg, Avg, Std Img and Vox 
Siz, Uniform Resolution” in ADNI. 
2.2.3. MRI Processing  
FreeSurfer pipeline (version 5.3.0) [48] was applied to the MRI scans under 
centos4_x86_64 Linux system to produce cortical and subcortical volumetric variables. 
The original MRI scan was first mapped to the standard MNI 305 space, yielding the 
image referred to as T1.mgz, which was used as the reference image in the following 
registration procedure. Based on the T1 image, the corresponding image file termed as 
aparc+aseg.mgz provides the FreeSurfer parcellated and segmented cortical and 
subcortical regions. CTh, surface area and volume were then calculated as morphological 
variables on each of the 34 cortical regions for both hemispheres as well as the volume on 
each of the 45 subcortical regions of the whole brain.  
Multiple morphological variables were then generated for the labeled regions. Specially, 
there are 9 measurements for each cortical regions: surface area, gray matter volume, 
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average thickness, thickness standard deviation, integrated rectified mean curvature, 
integrated rectified Gaussian curvature, folding index, intrinsic curvature index, and 
white matter volume, and 3 measurements for the subcortical regions: volume, mean 
intensity and intensity standard deviation. The estimated total intracranial volume (ICV) 
is also provided.  
2.2.4. PET processing 
In order to quantify the Aβ load from the PET scans, FMRIB Software Library (FSL) 
[49] was then used to co-register the PET image to the aforementioned T1 image. 
Considering the relatively low resolution of the PET image and to utilize as much 
information from PET as possible, the AV45 PET scan, with the skull, were co-registered 
linearly (i.e., trilinear interpolation) with 12 degrees of freedom (DOF) onto the T1 
image. Such a registration process guaranteed that the AV45 PET image had the same 
accurate segmentation and parcellation as in the MRI. Thus, the mean Aβ load of each of 
the FreeSurfer defined regions can be calculated, which was used later to calculate the 
global Aβ load value.   
2.2.5. Global Aβ Load Calculation 
The registered AV45 PET with the aparc+aseg image was first inspected to ensure 
appropriate calculations of the mean Aβ uptake value (SUV) of all the FreeSurfer-defined 
regions (ROIs) as expressed in (2.1). 
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SUVROIk =
Vali
i=1
NROIk
∑
NROIi
       (2.1) 
where SUVROIk  represents the mean Aβ uptake value of the region ROIk, with NROIk
representing the number of voxels labeled as region ROIk in the aparc+aseg image, and 
Vali represents the intensity of voxel i in the PET scan. 
The SUV of the whole cerebellum, consisting of 4 subcortical regions (left/right 
cerebellum white matter and left/right cerebellum cortex), was then calculated using (2), 
accounting for the varying sizes of the subregions. The SUV of the global cortical was 
computed in the same way, i.e., volume-weighted mean of all 68 cortical ROIs as 
expressed in (2.2).  
SUVCB =
SUVSR1 ×VSR1 + SUVSR2 ×VSR2 +!+ SUVSRN ×VSRN
VSR1 +VSR2 +!+VSRN
    (2.2) 
where CB represents the combined region of N ROIs (4 and 68 for the cerebellum and 
global cortical, respectively, with SUVSRi representing the SUV of ROIi, and VSRi 
represents the volume of ROIi. 
Finally, each regional, as well as global SUV was normalized by the SUV of the whole 
cerebellum to get the regional and global AV45 standardized uptake value ratio (rSUVR 
and gSUVR). Such SUVR measure was then used to represent the Aβ load in our 
analysis. 
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2.2.6. Feature Extraction Model 
To make the extracted image features match the information of the EMCI diagnosis as 
much as possible, and to control the number of features at a reasonable level, we 
proposed the ROI-based feature extraction model shown in Fig. 2. For each region, one 
feature was extracted based on its performance related to the EMCI phenotype, i.e., the 
image feature values were predicted by base learners trained on raw neuroimaging 
morphological variables and amyloid load. 
Specifically, for each ROI, the corresponding image feature was defined as the predictive 
probability of being EMCI. The random forest algorithm was considered as the classifier, 
i.e. the base learner, using all available morphological variables (9 and 3 for cortical and 
subcortical regions, respectively), regional amyloid load (rSUVR) along with the global 
information, such as ICV and global amyloid load (gSUVR), as predictors, and the 
diagnosis group as output.  
Random forest is an ensemble machine learning algorithm for classification and 
regression. It is a combination of multiple simple decision trees, and use the mode of the 
classes or mean prediction as the output for the classification and regression, respectively 
[50].   
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Fig. 2. Region-based neuroimang feature extraction model illustration for left entorhinal ROI in the CN vs. 
EMCI classification. 
 
2.2.7. Classification Model 
The classification model follows the stack ensemble classification model framework. 
Here, we used the 10-fold stacking pipeline. Specifically, the 2-level classification 
framework consists of the following major steps: 
 
1. Split the training data in 10 sets: train_1, tain_2, …. , and train_10; 
2. For each ROI, train the individual base leaner model, i.e. random forest, on 
{train_1, taint_2, … train_9},  and create predictions, i.e., the probability of 
being EMCI for train_10; 
3. Repeat step 2 nine times, i.e., train the same models on {train_1, …, train_i-1, 
train_i+1, train_10} and create predictions for train_i, i=2, 3, …10; 
4. Rank the ROIs by the accuracy, filter out ones with accuracy less than the 1st 
quartile;   
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5. Train the top layer classifier, i.e., SVM (polynomial kernel) model, on the 
remaining predictions of the base learner models that has been make on the 
training data in step2 and step 3 along with patients’ demographic information; 
6. For validation, first train the random forest models on the entire training data per 
ROI, and create predictions for the test data; 
7. Finally, predict using the SVM (polynomial kernel) with the predictions of the 
base learner models that has been make for test data. 
To avoid over-fitting of the ensemble model, the out-of-bag predictions for the training 
data were used as the predictors in step 5 to train the SVM classifier.  
The proposed classification model is evaluated using 10-fold cross-validation. 
Specifically, we randomly divided the dataset into 10 parts and repeated the 
aforementioned classification framework 10 times. At each time, nine of the 10 subsets 
were used as training data in the aforementioned classification framework, while the 
remaining one were used as the testing dataset.  
Once the predictions of all 10 subset are created, the true positive (TP), true negative 
(TN), false positive (FP), false negative (FN) can be counted. In the context of CN vs. 
EMCI classification, those terms means the number of subjects correctly diagnosed as 
EMCI, the number of subjects correctly diagnosed as CN, the number of CN subjects 
misdiagnosed as EMCI, and the number of EMCI subjects who are diagnosed as CN, 
respectively. The performance of the proposed classification model are measured by the 
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accuracy (ACC), sensitivity (SEN), and specificity (SPE) which are defined as 
(TP+TN)/(TP+TN+FN+FP), TP/(TP+FN), and TN/(FP+TN), respectively. For each 
binary classification, the more serious stage are labeled as positive class, for example, 
EMCI is the positive class for the CN vs. EMCI classification, while LMCI is the positive 
class for the EMCI vs. LMCI classification. 
2.3. Results and Discussion 
2.3.1. Performance of the proposed and raw imaging features 
Fig. 3 illustrates the ROC curves of the regional SUVR normalized by gSUVR, cortical 
thickness, regional amyloid load, gray matter volume normalized by ICV, white matter 
volume normlalized by ICV, global amyloid load (gSUVR), and the proposed imaging 
feature for the left entorhinal. The results show that the proposed imaging feature 
outperforms other single imaging biomarkers with the area under the curve (AUC) value 
of 73.2, indicating that it dose fuse the complementary information provided by different 
types of morphological and functional imaging measurements.  
2.3.2. Compare the baseline classification with proposed ensemble classification 
model 
To validate the proposed feature extraction model, we also run the SVM (Polynomial 
kernel) on the original imaging features as the baseline. Features do not show significant 
difference between CN and EMCI groups by T test, were filtered out, i.e., only features 
with uncorrected p-value less than 0.05 are considered as the predictors in the baseline 
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model. In addition, we tested the independent and combined performance of the MMSE 
score by training the classifiers using single MMSE and combination MMSE with other 
imaging features, respectively. The accuracy, sensitivity, and specificity of those models 
are listed in Table 5. Compared with the baseline model, the proposed method effectively 
improved the diagnosis of EMCI from CN (ACC = 72.5% / 69.4 for proposed/baseline), 
LMCI (ACC = 72.3% / 71.9%), and AD (ACC = 87.6% / 87.4%). Such patterns were 
enhanced when including the MMSE score as additional predictor.   
MMSE score is one of the key assess measurements of the diagnosis of AD, patients with 
AD normally have MMSE score less than 24, while for the CN subjects, the range is 
around 26 to 30. As expected, using MMSE score only, we can diagnosis AD from CN, 
EMCI, or LMCI with the accuracy of 96.3%, 90.7%, and 86.8%, respectively. However, 
MMSE is insensitive for the early stage of AD, especially for the EMCI stage. The CN 
vs. EMCI, CN vs. LMCI, and EMCI vs. LMCI models only have accuracy of 62.5%, 
68.6%, and 63.9%, respectively. When combing the MMSE with our proposed features, 
the accuracy of CN vs. EMCI and EMCI vs. AD reached 75.3% and 94%, 3% and 6.4% 
higher than the models using proposed features only, while accuracy of EMCI vs. LMCI 
is decreased to 71.3%. 
2.3.3. Comparison with other feature extraction techniques 
The obtained results are comparable with or better than previously proposed approaches, 
especially for the more challenging classification problems: CN vs. EMCI (72.3% / 
75.3% with/without MMSE), EMCI vs. LMCI (72.3% / 71.3%), and LMCI vs. AD 
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(70.7%  / 84.3%). For instance, Guerrero et al., Prasad et al., and Tripathi et al. reported 
CN vs. EMCI accuracy rates of 65%, 59.2%, and 75.4%, respectively. Prasad et al., 
Shakeri et al., and Tripathi et al. stated EMCI vs. LMCI accuracy values of 63.4%, 
63.0%, and 71.0% repectively. Our model also outperforms on the EMCI vs. AD 
classification, with the accuary of 87.6% / 94.0%, compared with other models proposed 
by Shakeri et al. (81.0%) and Tripathi et al. (86.2%) (Table 6). 
 
Fig. 3. ROC curves of different imaging biomarkers and the proposed imaging feature of 
the left entorhinal ROI for the CN vs. EMCI classification. 
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Table 5. Comparison of the classification accuracy (ACC), sensitivity (SEN), and specificity (SPE) (%) 
values of baseline with proposed feature extraction based model for 6 different pairs of binary 
classification 
 CN vs. EMCI  CN vs. LMCI  CN vs. AD 
 ACC SEN SPE  ACC SEN SPE  ACC SEN SPE 
baseline 69.4 69.4 69.4  76.6 77.1 76.3  92.6 91.0 93.6 
proposed 72.5 73.0 71.9  76.4 79.9 74.6  91.1 88.6 92.7 
MMSE 62.5 63.2 61.3  68.6 67.5 69.3  96.3 91.8 99.6 
Baseline+MMSE 70.5 70.0 71.2  77.3 77.2 77.3  94.3 95.3 93.8 
Propsed+MMSE 75.3 75.2 75.3  77.5 78.3 77.0  96.5 96.2 96.8 
 EMCI vs. LMCI  EMCI vs. AD  LMCI vs. AD 
 ACC SEN SPE  ACC SEN SPE  ACC SEN SPE 
baseline 71.9 73.0 71.6  87.4 83.9 89.1  74.1 71.3 76.3 
proposed 72.3 73.8 71.9  87.6 87.0 87.9  70.7 71.7 70.1 
MMSE 63.9 65.5 63.7  90.7 79.3 99.6  85.8 76.7 98.0 
Baseline+MMSE 72.7 73.8 72.4  90.7 88.7 91.7  80.6 78.5 82.4 
Propsed+MMSE 71.3 71.2 71.3  94.0 92.8 94.7  84.3 84.1 84.5 
 
 
Table 6. Comparison of the classification accuracy (ACC), sensitivity (SEN), and specificity (SPE) (%) 
values of the proposed model with others for 6 different pairs of binary classification 
 CN vs. EMCI  CN vs. LMCI  CN vs. AD 
 ACC SEN SPE  ACC SEN SPE  ACC SEN SPE 
Guerrero et al. (2014) 65 61 69  - - -  86 86 85 
Prasad et al.  (2014) 59.2 - -  62.8 - -  78.2 - - 
Shakeri et al. (2016) 56 52 60  59 52 65  84 73 89 
Tripathi et al. (2017) 75.4 74.0 76.6  72.6 71.37 74.3  88.7 83.1 91.5 
Propsed+MMSE 75.3 75.2 75.3  77.5 78.3 77.0  96.5 96.2 96.8 
 EMCI vs. LMCI  EMCI vs. AD  LMCI vs. AD 
 ACC SEN SPE  ACC SEN SPE  ACC SEN SPE 
Guerrero et al. (2014) - - -  - - -  - - - 
Prasad et al.  (2014) 63.4 - -  - - -  - - - 
Shakeri et al. (2016) 63 62 66  81 70 82  67 58 73 
Tripathi et al. (2017) 71.0 75.6 65.5  86.2 83.2 88.2  76.8 79.8 74.2 
Propsed+MMSE 71.3 71.2 71.3  94.0 92.8 94.7  84.3 84.1 84.5 
 
2.4. Conclusion 
We have proposed an ensemble framework based on region-based neuroimaging feature 
extraction model for the classification of Alzheimer’s Disease.  The features were 
extracted as the probability of being disease form the base learner trained on all regional 
morphological variables provided by FreeSurfer, regional amyloid load, and the global 
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information such as ICV and global amyloid load. Experimental evaluation on the ADNI 
dataset demonstrates the effectiveness of our approach especially in classifying CN vs. 
EMCI, EMCI vs. LMCI, and EMCI vs. AD, indicating that the proposed features 
preserved the sensitivity to change in a single brain region especially at the very early 
stage of the disease and might be used as the potential effective imaging biomarker 
especially for the EMCI diagnosis and clinical study. 
  
 26 
CHAPTER III  
REGIONAL IMAGE FEATURES MODEL FOR THE GENOME-WIDE 
ASSOCIATION STUDY OF ALZHEIMER’S DISEASE 
3.1.  Goal 
Compared to the traditional disease phenotypes (with or without disease), we can obtain 
closer association or even better insight by introducing intermediate phenotypes, which 
are often continuous values, [51-54]. Recently, brain imaging is commonly considered as 
a source of intermediate phenotypes that augment our understanding of the subtle and 
complex relationship between genetics and disease phenotypes, which is often termed as 
imaging genetics. The imaging genetics takes into consideration the fact that certain 
image-based features can serve as promising brain phenotypes for discovering the disease 
related genes.  
One of the main challenges in the area of imaging genetics is the extremely high 
dimensionality of image and genetic data (millions of voxels or SNPs), albeit with a 
relatively small number of subjects in AD research (few thousands). To overcome this 
challenge, some researchers proposed algorithms that consider only few image features 
such as the intensities of selected voxels [55, 56], regional cortical atrophy [18, 57], and 
brain activation [58]; or only few SNPs using univariate methods, i.e., performing a 
standard statistical test on each pair of a candidate SNP and related imaging features [57-
59]. To control the false positive rate, multiple comparisons adjustment is needed [60]. 
This may reduce the power of the test and hence overlook the weaker SNPs that jointly 
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create an additive effect. To overcome such shortcomings, multivariate techniques, such 
as parse reduced rank regression (sRRR) [56], sparse Partial Least Squares (sPLS) [61] 
and Canonical Correlation Analysis (CCA) [62] have been introduced in the more recent 
literature. The sPLS performs better compared to others [62]. However, these methods do 
not consider the diagnosis information in their model, and thus the detected SNPs may 
not be immediately related to AD. 
In this study, we propose a regional image feature extraction model for obtaining image 
features associated with the disease, and then use sPLS regression model to detect the 
SNPs associated with these extracted image features. Thus, instead of modeling a direct 
link between genetic variants and disease label, we captured disease information 
indirectly.  
3.2. Material 
3.2.1. Study Participants 
For this particular study, given its set objectives, 103 AD patients and 139 normal 
controls (CN) form ADNI1 with available whole genome imputed genotypes information 
was considered. All individuals underwent a 1.5 Tesla T1-weighted MRI scan with a 
cognition assessment at baseline. The demographic characteristics of the participants 
were shown in Table 7. 
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Table 7. Participants demographic and clinical information for the imaging genetic study 
 
Characteristics CN (139) AD (103) p-valuea 
Female/Male 62/77 49/54 0.7431 
Age 76.2(4.9)b 75.1(7.6) 0.1558 
Education 16.2(2.6) 14.8(3.2) 0.0003 
MMSE 29.17(1.02) 23.54(1.95) 0.0000 
a Significant group differences (T test for continuous and Chi-square test for categorical values, 
significance level is 0.05 by default) 
 
b Values are represented as mean(standard deviation) 
 
 
3.2.2. Image Processing 
Each MRI image was processed sequentially by the FreeSurfer (Version 5.3.0) 
(http://freesurfer.net, [63]), Advanced Normalization Tools (ANTs) 
(http://picsl.upenn.edu/software/ants/, [64]) and the Mindboggle software 
(http://www.mindboggle.info/, [65]).  Firstly, the FreeSurfer was used to transform the 
original MRI to the standard MNI 305 space, followed by skull-stripping, segmenting, 
and delineating cortical and subcortical regions, and to generate thereafter labeled cortical 
surfaces, and labeled cortical and neocortical volumes. The ANTs software was then used 
to perform the brain volume extraction, segmentation, and registration-based labeling. 
Finally, the Mindboggle software package was executed to automatically analyze the 
shape of anatomical labels and extract features from outputs of FreeSurfer and ANTs. 
Ultimately, 43 measures of each of the 50 neocortical brain regions (ROI) are obtained as 
indicated in Table 8. Those 50 ROIs include caudal anterior cingulate, caudal middle 
frontal, cuneus, entorhinal, fusiform, inferior parietal, inferior temporal, lateral occipital, 
lateral orbitofrontal, lingual, medial orbitofrontal, middle temporal, parahippocampal, 
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paracentral, pars opercularis, pericalcarine, postcentral, precentral, precuneus, superior 
frontal, superiorparietal, superior temporal, supramarginal, transverse temporal, and 
insula on both left and right hemispheres. 
Table 8. The 43 Statistical summaries for each region 
Measure Type Number of statistical measures 
Surface Area  1 
Thickness 8 - median, MAD, mean, SD, skew, kurtosis, .25a, .75b 
Travel depth 8 - median, MAD, mean, SD, skew, kurtosis, .25, .75 
Geodesic depth 8 - median, MAD, mean, SD, skew, kurtosis, .25, .75 
Convexity 8 - median, MAD, mean, SD, skew, kurtosis, .25, .75 
Mean curvature 8 - median, MAD, mean, SD, skew, kurtosis, .25, .75 
Thickness.thickinthehead 1 
Volume 1 
a first quartile of the corresponding measure type 
 
b third quartile of the corresponding measure type 
 
3.2.3. Genetic Data Processing 
The samples were genotyped on the Illumina Human610-Quad BeadChip or the Illumina 
HumanOmniExpress BeadChip. Considering the variety of SNP genotyping platforms, 
genetic data were imputed to a common reference set. The pre-impute quality control 
(QC) threshold and methods applied were as follows: All genome-wide association 
studies (GWAS) data are mapped to hg19/b37 positions and flipped to plus strand; the 
minor allele frequency (MAF) < 0.05; SNP Call Rate < 0.98; SAMPLE Call Rate < 0.98; 
Hardy–Weinberg equilibrium (HWE) < 0.001. Then, QC'd Batch 1 and 2 genotypes were 
pre-phased prior to SNP imputation using SHAPEITv2. Furthermore, the SNP imputation 
was performed using IMPUTE2. Overall, 12,568,804 SNPs were provided by ADNI. 
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3.3. Method 
3.3.1. ROI-based feature extraction 
To make the extracted image features match the information of the AD diagnosis as much 
as possible, and to control the number of features at a reasonable level, we proposed the 
ROI-based feature extraction model shown in Fig. 4. For each region, one feature was 
extracted based on its performance related to the AD phenotype, i.e., the image feature 
values were predicted by base learners trained on raw neuroimaging morphological 
variables (Table 8). 
 
Fig. 4. The flowchart illustrating the genome-wide association study using proposed ROI-based feature 
extraction model 
 
Specifically, for each ROI, the corresponding image feature was defined as the predictive 
probability of being AD. The Support Vector Machine (SVM) with a Radial Kernel 
model [66] was considered as the classifier, i.e. the base learner, using all 43 
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measurements as predictors, and the diagnosis group as output. After tuning the 
parameters based on the 10-fold cross-validation accuracy performance, we predicted 
each subject using the final model, and set the prediction probability of AD as the image 
feature of that specific ROI. Overall, 50 image features were extracted and were used as 
the brain phenotypes in the following regression model to detect the SNPs of interest. 
3.3.2. SNPs Selection 
To reduce the dimension of the genetic data, we first eliminated SNPs that do not satisfy 
the following QC criteria: MAF≥0.05; an HWE dose not showing significant difference 
at level 0.005; and with the SNP call rate ≥0.9. Chi-squared test was then conducted for 
each remaining SNP. Only SNPs that show significant difference between CN and AD 
group were considered in the following study, i.e. uncorrected p-value < 0.001. After 
filtering, 3478 out of the total 12,568,804 SNPs were finally selected. The count of minor 
alleles (0, 1, or 2) was used to represent the SNP. 
3.3.3. Sparse partial least squares regression 
The partial least squares regression (PLS) is based on the latent decomposition and could 
handle multicollinearity. It is considered to model the associations between two sets of 
variables via a small number of unobserved latent variables (LV), which are linear 
combinations of the original variables. Assume there are K hidden components, the PLS 
regression model builds successive and orthogonal LV for each set such that at each step 
the covariance between the pair of LVs is maximal (3.1). 
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max uk = vk =1cov Xk−1uk,Yk−1vk( )     (3.1) 
 
where k represents the k-th step to get the k-th hidden components. Elements Uk  and Vk  
define the weight vectors for the linear combinations of the variables of sets Xk−1  and 
Yk−1 , respectively. Xk−1  and Yk−1  are the residuals of sets X and Y after their regression on 
the k-1 pervious LVs (3.2). 
Xk−2 = TPt + Xk−1
Yk−2 = TQt +Yk−1
     (3.2) 
 
the T matrix produces the K linear combinations, P and Q are matrices of coefficients, 
and Xk−1  and Yk−1  are matrices of residuals. Considering that the LVs of the PLS have 
contributions from all the predictors, it is hard to make adequate interpretations in the 
presence of a large number of noise variables. Chun and Keles [67] proposed the sparse 
partial least squares regression model expressed in (3.3) by imposing additional L1 
penalization to (3.1), 
min uk = vk =1− cov Xk−1uk,Yk−1vk( )+ λX u 1 + λY v          (3.3) 
 
where λX and λY  are the L1-penalization parameters for the weight vectors of X and Y, 
respectively. In the context of this study, X consists of the 3478 selected SNPs after 
filtering, and Y includes the 50 extracted image features. Based on the 10-fold cross-
validated mean-squared prediction error, the optimal model with parameters K = 2 and 
λX = λY = 0.9was employed. 
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3.4. Results 
3.4.1. The Feature Extraction Model Evaluation 
The principal components analysis (PCA) was performed on the 50 extracted features, 
and the first two principal components (PC1 and PC2) separated the CN and AD subjects 
clearly, which means that those extracted features do capture the expected disease 
information (Fig. 5a). The feature that contributes most to the PC1 is extracted from the 
left inferior temporal, and for the PC2, it is from the right precentral. Fig. 5b shows the 
plot of those two features. Fig. 6 shows the accuracy obtained from 50 final SVM 
models. The top 5 ROIs entorhinal, fusiform, middle temporal, inferior temporal, and 
parahippocampal are all AD vulnerable regions [68], which provides credence to the 
method for extracting base learner derived features. 
3.4.2. Genetic association results 
The sPLS models finally detected 15 significant SNPs (Table 9).  14 SNPs are located on 
chromosome 19 and have been reported as correlated with AD [69-71]. Among them, 
rs769449 (APOE4), rs429358 (APOE), rs73052335 (APOC1) rs12972970 (PVRL2), 
rs6857 (PVRL2), rs2075650 (TOMM40), rs34404554 (TOMM40), rs11556505 
(TOMM40) are frequently reported as strongly correlated with AD and all are on 
chromosome 19 [18, 19, 21, 55, 72]. The rs917100 located on chromosome 8 was also 
detected. The performance of those 15 SNPs in terms of the coefficient estimate of all 50 
image-based features was shown in the heatmap given in Fig 7.  
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Fig. 5. Principal Component Analysis. a The PCA map of extracted image features for CN and AD groups. 
x-axis is the fist principal components (PC1) and y-axis is the second principal components (PC2); b Image 
features plot. Features extracted from the left inferior temporal and the right precentral contributes most for 
the PC1 and PC2 respectively. 
 
 
 
 
 
Fig. 6. The accuracy of 50 final SVM(Radial) Models (10-fold cross validation). One model for each brain 
region. 
 
Concerning the relationship to ROI-based features, rs12972970 (PVRL2), rs12972156, 
rs34342646, rs71352238, rs2075650 (TOMM40), rs34404554 (TOMM40), rs11556505 
(TOMM40), and rs142042446 show very similar patterns, those SNPs also contribute 
negatively for both the first and second LV in the sPLS regression model (Table 9). 
While rs769449 (APOE4), rs429358 (APOE), rs73052335 (APOC1), rs10414043 (APOE 
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(distance=3063), APOC1 (distance=2208)), and rs7256200 (APOE (distance=3285), 
APOC1(distance=1986)) have stronger correlation with some AD vulnerable regions, 
such as entorhinal, middle temporal and precuneus than the aforementioned SNPs, and 
they contribute negatively for the first LV but positively for the second LV. The 
rs917100 show similar pattern with APOE and APOC1 genes in the contribution to the 
LVs, but has stronger associations with the image features. 
Table 9. Fifteen SNPs Selected by sPLS model 
SNP Chromosome Position Gene Comp1 Comp2 
rs769449 19 45410002 APOE -0.00499 0.00255 
rs73052335 19 45420082 APOC1 -0.00495 0.00537 
rs10414043 19 45415713 APOE(dist=3063),APOC1(dist=2208) -0.00489 0.00384 
rs7256200 19 45415935 APOE(dist=3285),APOC1(dist=1986) -0.00489 0.00384 
rs12972156 19 45387459  -0.00481 -0.00286 
rs12972970 19 45387596 PVRL2 -0.00481 -0.00286 
rs34342646 19 45388130  -0.00481 -0.00286 
rs71352238 19 45394336  -0.00481 -0.00286 
rs2075650 19 45395619 TOMM40 -0.00481 -0.00286 
rs34404554 19 45395909 TOMM40 -0.00481 -0.00286 
rs11556505 19 45396144 TOMM40 -0.00481 -0.00286 
rs429358 19 45411941 APOE -0.00480 0.00438 
rs142042446 19 45386467  -0.00470 -0.00446 
rs6857 19 45392254 PVRL2 -0.00468 0.00065 
rs917100 8 5591150  -0.00418 0.06374 
a The weights for each latent variable in the sPLS model. 
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Fig. 7. Heat map of the selected 15 SNPs by sPLS using extracted image features as responses. 
 
3.5. Conclusion 
We proposed and demonstrated an imaging feature extraction model and applied it on the 
whole ADNI genetic dataset to identify genetic variants associated with AD. The 
associations between imaging and AD were captured using SVM base learner for each 
brain region. The AD related genetic variants were then selected via the sPLS regression 
model. The proposed model can be widely employed to other GWAS study of 
neurological diseases. On the other hand, besides the volume and cortical thickness, the 
proposed imaging feature extraction model considers more detailed information of the 
brain regions and could be used as additional predictors to enhance the diagnosis model 
of AD, and to further explore the performance of brain regions on the progression of AD 
as well. 
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CHAPTER IV 
THE RELATIONSHIP OF BRAIN AMYLOID LOAD AND APOE STATUS TO 
REGIONAL CORTICAL THINING AND COGNITION 
4.1. Goal 
The relationship between APOE4 positive status (E4+) and higher Aβ load is well 
known, as is the relationship of both E4+ status and higher Aβ load to a greater risk for 
developing Alzheimer’s disease and a greater degree of neurodegeneration [23, 73-75]. 
However, the relationship of APOE4 status to neurodegeneration and cognitive decline, 
independent of Aβ load, and the relationship of Aβ load to neurodegeneration and 
cognitive decline, independent of APOE4 status, are not known and to our knowledge 
have not been studied thus far. 
In the present study, we examined both the combined and independent associations 
between global Aβ load, APOE4 status and regional coritcal thickness (CTh) among four 
different diagnostic groups in the ADNI sample, including cognitively normal (CN), 
early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI) or AD 
dementia participants. A unique aspect of this investigation was to determine the 
independent and combined effects of APOE4 status and Aβ load on regional CTh and 
cognition among individuals presenting with minimal (EMCI) or no overt memory 
impairment (CN). 
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4.2. Materials and Methods 
4.2.1. Data 
Data used in the preparation of this article were obtained from the ADNI database 
(adni.loni.usc.edu). Evaluations included: (1) Medical and neurological evaluation and 
routine labs; (2) Clinical Dementia Rating (CDR) scale, which was used as the index of 
functional ability [76]; (3) neuropsychological assessment, including the ADAS Cog 13 
(ADAS13) and Mini-Mental State Exam (MMSE) subtests, used as the global index of 
cognitive ability [77], and the Rey Auditory Verbal Learning Test (RAVLT) and subtests, 
used as the index of memory performance [78]; (4) volumetric MRI; and (5) 18F-AV45 
amyloid PET scans. The time gap between MRI and PET scans was less than 3 months. 
A blood sample for assessment of APOE genotype was also obtained. 
Baseline demographic, clinical and APOE data were compared for 906 subjects, 
diagnosed as CN (251), EMCI (297), LMCI (196), or AD (162), as shown in Table 10. 
Subjects with one or more APOE4 alleles, i.e. APOE4 carriers, were classified as E4+, 
while those with no APOE4 alleles, i.e. APOE4 non-carrier, were classified as E4-. 
4.2.2. Image Processing  
Image processing pipeline is same as descripted in Chapter II. In this study, regional CTh 
in AD signature regions, previously identified by several groups [79, 80] was evaluated. 
These include the entorhinal cortex (ERC), parahippocampal gyrus (PHG), inferior 
temporal gyrus (ITG), temporal pole (TP), medial orbital frontal gyrus, superior temporal 
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gyrus, rostral middle frontal gyrus, inferior parietal lobule (including angular gyrus), 
superior parietal lobule, supramarginal gyrus, precuneus, posterior cingulate gyrus and 
the mean CTh based on the aforementioned regions. 
In terms of AV45 PET, only global amyloid load was considered. A widely used 
threshold value of 1.10 is used here to delineate Aβ positive (Amy+, SUVR > 1.10) and 
Aβ negative (Amy-, SUVR <= 1.10) status [81, 82]. 
Table 10. Participant clinical information 
 CN (n = 251) 
EMCI 
(n = 297) 
LMCI 
(n = 196) 
AD 
(n = 162) F value 
Female/Male 128/123 132/165 85/111 68/94 4.36b 
E4-/E4+ 184/67 169/128 92/104 54/108 70.32***c 
Age 75.5(6.5)a 71.5(7.4) 73.8(8.1) 74.9(7.8) 14.85*** 
EDUCATION 16.4(2.6) 16.0(2.7) 16.3(2.7) 15.8(2.7) 2.71* 
Type of Cognitive Test 
CDRSB 0.05(0.2) 1.31(0.78) 1.76(1.06) 4.84(2.07) 633.12*** 
ADAS13 9.09(4.54) 12.72(5.51) 17.9(7.5) 31.55(8.81) 434.53*** 
MMSE 29.04(1.23) 28.32(1.57) 27.61(1.85) 22.77(2.71) 448.73*** 
RAVLT_immediate 45.35(10.58) 39.47(10.8) 33.21(10.82) 22.31(7.03) 183.76*** 
RAVLT_learning 5.74(2.44) 5.29(2.45) 3.92(2.58) 1.91(1.77) 102.04*** 
RAVLT_% forgetting 36.22(27.79) 46.98(29.72) 67.37(31.34) 90.1(19.91) 142.34*** 
a Values are represented as mean(sd), except gender and APOE gene status, which are frequencies 
instead 
 
b Significant group differences test (ANOVA for continuous and Chi-square test for categorical values, 
significance level is 0.05 by default) 
 
c p<.1; *p<.05; **p< .01; ***p< .001  
 
 
4.2.3. Statistical Methods 
The statistical analysis was performed using R software (R 3.3.0) [83] and the default 
significant level was determined as 0.05. To examine the independent effect of Aβ load 
on regional CTh, by controlling for the effects of APOE4 status, two-way analysis of 
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covariance (ANCOVA), i.e., 4 (diagnosis: CN, EMCI, LMCI, AD) by 2 (Aβ load status: 
Amy+, Amy-) ANCOVA, was conducted per region, with APOE4 status (E4+, E4-) 
entered as an categorical covariates.  
Similarly, to investigate the individual effects of APOE4 status after controlling for 
global Aβ load, a series of 4 (diagnosis: CN, EMCI, LMCI, AD) by 2 (APOE4 status: 
E4+, E4-) ANCOVAs were conducted, with global Aβ load (SUVR) as an interval level 
covariate. As a complementary analysis, to assess the earliest individual effects of 
APOE4 status, a series of 2 (diagnosis: CN, EMCI) by 2 (APOE4 status: E4+, E4-) 
ANCOVAs were performed among 548 individuals diagnosed as CN or EMCI.   
To examine the earliest combined effects of both APOE4 status and Aβ load status on 
regional CTh and on several cognitive variables (MMSE, RAVLT sub scores, and 
ADAS13 score), we focused on above-mentioned CN and EMCI participants (n = 548), 
and divided them into four groups: E4-/Amy- (n = 241), E4-/Amy+ (n = 112), E4+/Amy- 
(n = 73), and E4+/Amy+ (n = 122). A series of one-way ANCOVAs were conducted, 
using age as a covariate, and with CTh or cognitive scores as the dependent variables. 
Multiple comparison correction was performed in all aforementioned ANCOVA analyses 
to control the false discovery rate (FDR). Statistically significant results (FDR-adjusted p 
value < 0.05) were further examined using post hoc Tukey HSD test. 
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4.3. Results 
E4+ status was associated with higher Aβ load across all diagnostic groups, as shown in 
Table 11 and Fig. 8. 
4.3.1. Effect of Aβ Load Status on CTh after Controlling for APOE4 Status 
Results for the left hemisphere only are reported, since findings in both the left and right 
hemispheres were similar. As can be seen in Table 12 and Fig. 9, there was a statistically 
significant main effect for Aβ load, accounting for the effect of APOE4 status, on CTh, 
for all brain regions examined, with the exception of the temporal pole (TP), superior 
frontal gyrus and rostral middle frontal gyrus. The most significant effects were noted in 
the inferior temporal gyrus (ITG) (F = 31.18, diff (Amy+ - Amy-) = -0.099), inferior 
parietal lobule (F = 20.82, diff = -0.068), precuneus (F = 16.55, diff = -0.058), the mean 
CTh for all regions (F = 15.6, diff = -0.046), entorhinal cortex (ERC) (F = 14.59, diff = -
0.159), and supramarginal gyrus (F = 10.98, diff = -0.051). In all these regions Amy+ 
status was associated with reduced CTh, adjusting for the effects of APOE4 status. 
Table 11. Effect of APOE4 status on global amyloid load (SUVR) in different diagnostic groups 
 E4- E4+ t testa P value 
CN 1.079(0.16) 1.178(0.2) -3.65649 0.00021 
EMCI 1.115(0.18) 1.246(0.21) -5.76863 0 
LMCI 1.147(0.23) 1.368(0.21) -7.12632 0 
AD 1.271(0.26) 1.439(0.16) -4.32684 0.00002 
a H0: SUVR(E4-) = SUVR(E4+) vs H1: SUVR(E4-) < SUVR(E4+) 
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Fig. 8. Differences in mean amyloid load (18F-AV45) SUVR for each diagnostic group 
between E4- and E4+ participants. The error bar on the barplot represents the standard 
error value. 
Table 12 also shows a strong main effect for diagnosis. Using post hoc tests (Tukey 
HSD), it was found that CTh was reduced among AD participants compared to the three 
other diagnostic groups, and also among LMCI participants, as compared to EMCI and 
CN participants. This pattern appeared to hold for every brain region included in these 
analyses, with the exception of the superior parietal lobule, where EMCI participants had 
greater CTh than the other diagnostic groups, which did not statistically differ from each 
other. With rare exceptions, CTh was equivalent between CN and EMCI participants. In 
the supramarginal gyrus and precuneus, CTh was greater in EMCI than in CN 
participants. Statistically significant interaction terms (diagnosis with Aβ load status) 
were observed for the ITG and inferior parietal lobule, in which Amy+ status was 
associated with reduced CTh only in the LMCI and the AD stages.  
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Table 12. Effect of amyloid status on regional CTh, independent of APOE4 status (left hemisphere) 
 CN 
Amy- 165 
Amy+ 86 
EMCI 
Amy- 149 
Amy+ 148 
LMCI 
Amy- 66 
Amy+ 130 
AD 
Amy- 19 
Amy+ 143 
Fa 
Amyloid 
Fa 
Diagnosis 
post_hoc 
Tukey 
(Diagnosis) 
Fa 
Diagnosis 
by 
Amyloid 
Age 74.51(6.8)b 
76.75(5.7) 
69.19(7.4) 
73.46(6.8) 
73.68(9.4) 
73.61(7.3) 
77.49(8.2) 
74.38(7.7) 10.64**
c 15.79*** EMCI < All 4.78** 
Entorhinal 3.34(0.38) 
3.27(0.37) 
3.32(0.46) 
3.26(0.43) 
3.17(0.52) 
2.96(0.52) 
2.77(0.74) 
2.58(0.49) 14.59*** 42.18*** 
AD < All;  
LMCI < 
EMCI, CN 
1.56 
Parahippoc
ampal 2.67(0.34) 
2.58(0.41) 
2.66(0.36) 
2.67(0.31) 
2.52(0.39) 
2.5(0.4) 
2.44(0.39) 
2.31(0.35) 6.74** 15.6*** 
AD < 
EMCI, CN 
LMCI < 
EMCI, CN 
1.23 
Inferior 
temporal 2.66(0.16) 2.61(0.16) 
2.66(0.18) 
2.61(0.19) 
2.61(0.18) 
2.57(0.23) 
2.57(0.26) 
2.39(0.24) 31.18*** 13.86*** 
AD < All;  
LMCI < 
EMCI, CN 
3.13* 
Temporal 
pole 3.56(0.33) 3.53(0.36) 
3.48(0.37) 
3.5(0.34) 
3.5(0.35) 
3.35(0.45) 
3.08(0.63) 
3.11(0.51) 2.46 23.19*** 
AD < All; 
LMCI < 
CN 
1.99 
Medial 
orbitofront
al 
2.28(0.15) 
2.27(0.18) 
2.27(0.14) 
2.23(0.16) 
2.23(0.17) 
2.22(0.17) 
2.25(0.2) 
2.19(0.16) 8.14** 4.57** 
AD < CN; 
LMCI < 
CN 
1.3 
Superior 
frontal 2.48(0.17) 2.46(0.17) 
2.52(0.15) 
2.49(0.15) 
2.45(0.17) 
2.42(0.16) 
2.37(0.17) 
2.36(0.18) 3.79. 15.17*** 
AD < All; 
LMCI < 
EMCI 
0.14 
Rostral 
Middle 
Frontal 
2.15(0.14) 
2.15(0.15) 
2.18(0.13) 
2.15(0.12) 
2.14(0.14) 
2.11(0.13) 
2.09(0.16) 
2.07(0.15) 1.87 8.2*** 
AD < 
EMCI, CN 
LMCI < 
EMCI 
0.64 
Superior 
Parietal 
1.96(0.17) 
1.96(0.17) 
2.01(0.14) 
2.01(0.14) 
1.97(0.16) 
1.94(0.16) 
1.95(0.12) 
1.86(0.18) 6.08* 10.02*** 
EMCI > 
All 1.69 
Inferior 
Parietal 2.19(0.16) 2.18(0.17) 
2.23(0.14) 
2.21(0.15) 
2.2(0.14) 
2.13(0.16) 
2.18(0.18) 
2.02(0.2) 20.82*** 10.67*** 
AD < All; 
LMCI < 
EMCI 
4.78** 
Supramarg
inal 2.31(0.18) 2.31(0.18) 
2.37(0.15) 
2.34(0.16) 
2.3(0.17) 
2.26(0.17) 
2.26(0.19) 
2.16(0.18) 10.98*** 16.51*** 
AD < All; 
EMCI > 
LMCI, CN 
1.71 
Precuneus 2.14(0.17) 
2.12(0.17) 
2.19(0.14) 
2.15(0.15) 
2.14(0.16) 
2.1(0.15) 
2.11(0.14) 
1.99(0.18) 16.55*** 10.33*** 
AD < All; 
EMCI > 
LMCI, CN 
1.92 
Posterior 
Cingulate 
2.38(0.18) 
2.4(0.18) 
2.41(0.17) 
2.39(0.17) 
2.4(0.17) 
2.37(0.17) 
2.39(0.22) 
2.31(0.18) 4.25* 1.7  1.66 
 
Mean 
CTh_left 
 
2.30(0.13) 
2.29(0.14) 
2.33(0.11) 
2.31(0.12) 
2.28(0.13) 
2.24(0.13) 
2.23(0.15) 
2.15(0.14) 15.6*** 20.62*** 
AD < All;  
LMCI < 
EMCI, CN 
1.54 
a F value is adjusted for APOE4 Status (4 X 2 ANCOVA test) 
 
b Values are represented as mean(SD), upper is for Amy- group and lower is for Amy+ group 
 
c p<.1; *p<.05; **p< .01; ***p< .001 
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Fig. 9. Barplot of CTh among Amy- and Amy+ participants in 4 diagnostic groups for 12 brain regions. 
 
 
4.3.2. Effect of APOE4 Status on CTh after Controlling for Aβ Load 
From Table 13, it can be seen that the diagnostic group effect was similar to the pattern 
observed in Table 11, i.e., AD patients had less CTh than the other study groups and that 
LMCI participants had less CTh than EMCI and CN participants, while CTh was 
equivalent between CN and EMCI participants. An inspection of the regional CTh by 
APOE4 status in Fig. 10 shows that for most brain regions analyzed, CTh among CN and 
EMCI participants is numerically greater among those who are E4+ than E4-. However, 
the reverse is generally true among LMCI and particularly AD participants, for whom 
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CTh is generally lower among E4+ than E4- participants. After adjusting for global Aβ 
load (SUVR), there was a main effect for APOE4 status only in the ITG (diff(E4+ - E4-) 
= 0.048mm, F = 9.99,  p = 0.0016) and medial orbitofrontal gyrus (diff = 0.027mm, F = 
4.83, p = 0.028), in which it can be observed that CTh was overall greater among E4+ 
than among E4- participants (Fig. 10). Furthermore, the interaction term in Table 13 
shows significant difference only in the ERC, where the CTh is greater only among CN 
and EMCI participants who are E4+ as compared to those who are E4-, whereas among 
LMCI and AD participants, CTh is greater among E4- as compared to E4+ participants 
(Fig. 10). 
More importantly, when CN and EMCI subjects were analyzed independently (Table 14), 
E4+ status (controlling for Aβ load) was associated with increased CTh in the ERC (diff 
= 0.123mm, F = 9.68, p = 0.002), PHG (diff = 0.082mm, F = 6.02, p = 0.014), ITG (diff 
= 0.059mm, F = 12.56, p = 0.0004), and TP (diff = 0.091mm, F = 7.47, p = 0.006). 
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Table 13. Effect of APOE4 status on regional CTh, independent of Aβ load (left hemisphere) 
 CN 
E4- 184 
E4+ 67 
EMCI 
E4- 169 
E4+ 128 
LMCI 
E4- 92 
E4+ 104 
AD 
E4- 54 
E4+ 108 
Fa 
APOE4 
Status 
Fa 
Diagnosis 
post_hoc_Tuke
y (Diagnosis) 
Fa 
Diagnosi
s by 
APOE4 
Age 75.77(6.3)
b 
73.93(7.0) 
72.07(7.3) 
70.33(7.5) 
74.96(8.6) 
72.46(7.4) 
76.43(8.6) 
73.90(7.3) 29.12*** 12.89*** EMCI < All 0.44 
Entorhinal 3.30(0.38) 3.35(0.37) 
3.22(0.46) 
3.37(0.41) 
3.11(0.54) 
2.96(0.51) 
2.69(0.60) 
2.55(0.48) 0.02 68.18*** 
AD < All;  
LMCI < EMCI, 
CN 
4.84** 
Parahippo
campal 
2.62(0.38) 
2.68(0.34) 
2.64(0.32) 
2.70(0.34) 
2.50(0.39) 
2.52(0.39) 
2.37(0.38) 
2.31(0.34) 1.71 25.56*** 
AD < All;  
LMCI < EMCI, 
CN 
1.08 
Inferior 
temporal 
2.63(0.15) 
2.68(0.17) 
2.62(0.19) 
2.65(0.19) 
2.57(0.21) 
2.59(0.22) 
2.42(0.27) 
2.41(0.24) 9.99** 32.41*** 
AD < All;  
LMCI < CN 0.5 
Temporal 
pole 
3.53(0.35) 
3.60(0.32) 
3.45(0.37) 
3.53(0.34) 
3.42(0.40) 
3.38(0.44) 
3.11(0.53) 
3.10(0.52) 1.55 32.87*** 
AD < All;  
LMCI < CN 1.1 
Medial 
orbitofron
tal 
2.27(0.15) 
2.28(0.18) 
2.25(0.15) 
2.25(0.15) 
2.22(0.16) 
2.22(0.18) 
2.17(0.18) 
2.21(0.15) 4.83* 4.78** 
AD < EMCI, 
CN 0.53 
Superior 
frontal 
2.46(0.18) 
2.50(0.16) 
2.51(0.14) 
2.50(0.16) 
2.44(0.17) 
2.42(0.16) 
2.33(0.15) 
2.37(0.19) 2.01 22.2*** 
AD < All; 
LMCI < EMCI 1.49 
Rostral 
Middle 
Frontal 
2.14(0.15) 
2.15(0.14) 
2.18(0.12) 
2.15(0.13) 
2.13(0.14) 
2.11(0.12) 
2.05(0.16) 
2.08(0.15) 0 14.73*** 
AD < All; 
LMCI < EMCI 1.8 
Superior 
Parietal 
1.95(0.16) 
2.00(0.17) 
2.02(0.14) 
2.00(0.14) 
1.96(0.16) 
1.94(0.16) 
1.88(0.18) 
1.87(0.18) 0.57 18.66*** 
AD < All; 
LMCI < EMCI 1.7 
Inferior 
Parietal 
2.18(0.16) 
2.21(0.18) 
2.22(0.15) 
2.22(0.15) 
2.18(0.16) 
2.13(0.15) 
2.06(0.20) 
2.03(0.21) 0.1 25.75*** 
AD < All; 
LMCI < EMCI 2.11. 
Supramar
ginal 
2.30(0.18) 
2.34(0.17) 
2.35(0.15) 
2.36(0.16) 
2.29(0.17) 
2.26(0.17) 
2.17(0.19) 
2.17(0.18) 2.08 30.71*** 
AD < All; 
LMCI < EMCI 0.99 
Precuneus 2.12(0.16) 2.16(0.17) 
2.17(0.14) 
2.16(0.15) 
2.12(0.16) 
2.10(0.16) 
2.03(0.17) 
2.00(0.18) 0.36 22.49*** 
AD < All; 
LMCI < EMCI 1.39 
Posterior 
Cingulate 
2.37(0.18) 
2.42(0.18) 
2.41(0.17) 
2.38(0.17) 
2.38(0.16) 
2.38(0.18) 
2.33(0.20) 
2.31(0.18) 0.16 5.47*** AD < All 2.03 
 
MeanCTh
_left 
 
2.29(0.14) 
2.32(0.13) 
2.32(0.11) 
2.32(0.12) 
2.27(0.14) 
2.25(0.13) 
2.16(0.15) 
2.16(0.14) 2.31 38.84*** 
AD < All;  
LMCI < EMCI, 
CN 
1.25 
a F value is adjusted for global Aβ load (4 X 2 ANCOVA test) 
 
b Values are represented as mean(SD), upper is for E4- group and lower is for E4+ group 
 
c p<.1; *p<.05; **p< .01; ***p< .001 
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Fig. 10. Barplot of CTh among E4- and E4+ participants in 4 diagnostic groups for 12 brain regions.   
 
4.3.3. Combined Effect of APOE4 Status and Aβ Load Status on CTh among CN 
and EMCI Groups 
Among CN and EMCI groups, there were prominent age effects on CTh in almost every 
brain region, each with a different combination of Aβ and APOE4 status. However, once 
such age effects were accounted for, there was no difference in CTh measure in these two 
groups in any brain region.   
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Table 14. Effect of APOE4 status on regional CTh in CN and EMCI, independent of Aβ load  
(left hemisphere) 
 CN 
E4- 184 
E4+ 67 
EMCI 
E4- 169 
E4+ 128 
Fa 
APOE4 
Status 
Fa 
Diagnosis 
Fa 
Diagnosis by 
APOE4 
Entorhinal 3.30(0.38) 
b 
3.35(0.37) 
3.22(0.46) 
3.37(0.41) 9.68**c 0.26 1.92 
Parahippocampal 2.62(0.38) 2.68(0.34) 
2.64(0.32) 
2.70(0.34) 6.02* 0.71 0.06 
Inferior temporal 2.63(0.15) 2.68(0.17) 
2.62(0.19) 
2.65(0.19) 12.56*** 0.45 0.37 
Temporal pole 3.53(0.35) 3.60(0.32) 
3.45(0.37) 
3.53(0.34) 7.47** 3.88* 0.06 
Medial orbitofrontal 2.27(0.15) 2.28(0.18) 
2.25(0.15) 
2.25(0.15) 1.71 1.72 0.04 
Superior frontal 2.46(0.18) 2.50(0.16) 
2.51(0.14) 
2.5(0.16) 1.21 2.56 1.93 
Rostral Middle Frontal 2.14(0.15) 2.15(0.14) 
2.18(0.12) 
2.15(0.13) 0.45 1.23 2.46 
Superior Parietal 1.95(0.16) 2.00(0.17) 
2.02(0.14) 
2.00(0.14) 1.68 6.29* 4.65* 
Inferior Parietal 2.18(0.16) 2.21(0.18) 
2.22(0.15) 
2.22(0.15) 2.7 3.56. 1.81 
Supramarginal 2.30(0.18) 2.34(0.17) 
2.35(0.15) 
2.36(0.16) 3.81. 5.71* 1.17 
Precuneus 2.12(0.16) 2.16(0.17) 
2.17(0.14) 
2.16(0.15) 1.6 3.89* 3.58. 
Posterior Cingulate 2.37(0.18) 2.42(0.18) 
2.41(0.17) 
2.38(0.17) 0.56 0.02 5.87* 
Mean CTh_left 
 
2.29(0.14) 
2.32(0.13) 
2.32(0.11) 
2.32(0.12) 3.55. 2.52 2.72. 
a F value is adjusted for global Aβ load (2 X 2 ANCOVA test) 
 
b Values are represented as mean(SD), upper is for E4- group and lower is for E4+ group 
 
c p<.1; *p<.05; **p< .01; ***p< .001 
 
 
4.3.4. Combined Effect of APOE4 Status and Aβ Load Status on Cognitive 
Variables among CN and EMCI Groups 
From Table 15 and Fig. 11, it can be seen that after accounting for age, there was a 
significant effect on all assessed cognitive scores: (a) the E4+/Amy+ group showed more 
impairment than the E4-/Amy- group on the MMSE score (p <0.001); (b) the E4+/Amy+ 
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group was more impaired than the E4-/Amy- (p <0.001), as well as the E4-/Amy+ groups 
(p = 0.005) on the RAVLT (immediate) memory test; (c) the E4+/Amy+ group was more 
impaired that the E4-/Amy- group on the RAVLT percent forgetting (p = 0.018); and (d) 
the E4+/Amy+ group had more impaired ADAS13 scores as compared to all other 
combinations of E4+/- and Amy +/- (all p < 0.001).  
Table 15. Combined effect of APOE4 status and Aβ load status on cognitive scores among CN and 
EMCI groups 
 E4-Amy-  
(241) 
E4-Amy+ 
(112) 
E4+Amy-  
(73) 
E4+Amy+ 
(122) 
F_age F_E4Amya 
MMSE 28.93(1.35)b 28.54(1.39) 28.73(1.28) 28.16(1.73) 8.48**c 7.86*** 
E4+Amy+ < E4-
Amy-d 
RAVLT 
immediate 
44.00(10.98) 41.61(11.2) 43.73(10.8) 38.13(10.3) 36.85*** 8.23*** 
E4+Amy+ < E4- 
Amy-; 
E4+Amy+ < E4- 
Amy+ 
RAVLT 
Percent 
forgettinge 
38.79(29.8) 43.67(28.5) 39.8(26.94) 48.37(29.74) 8.5** 2.86* 
E4+Amy+ > E4- 
Amy- 
ADAS13e 10.00(4.82) 11.45(5.61) 9.70(5.17) 13.58(5.56) 21.9*** 13.51*** 
E4+Amy+ > All 
a F value is adjusted for age (One-way ANCOVA test) 
 
b Values are represented as mean(SD) 
 
c p<.1; *p<.05; **p< .01; ***p< .001 
 
d Post Hoc Tukey results with significant difference 
 
e Higher scores indicate worse performance  
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Fig. 11. Bar graph of scores on following cognitive tests: MMSE, RAVLT (immediate), RAVLT (% 
forgetting) and ADAS13. Individual bars represent the following groups of participants: E4-/Amy-; 
E4+/Amy-; E4-/Amy+ and E4+/Amy+. The colored asterisk (*p<.05; **p< .01; ***p< .001) on the E4-
/Amy- indicates a significant difference in score from the score for the corresponding color bar, i.e., 
E4+/Amy+ group, same as E4-/Amy+ bars in RAVLT (immediate) and ADAS13, as well as E4+/Amy- in 
ADAS13. There was no significant difference among E4-/Amy-, E4+/Amy-, E4-/Amy+ group. 
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4.4. Discussion 
This study represents a first attempt to disentangle the complex inter-relationships 
between Aβ load, APOE4 genotype, regional CTh and cognition among well-defined 
diagnostic groups in ADNI. Previous studies have shown that: (1) higher global Aβ load 
and E4+ status are associated with a greater risk of progression from CN to MCI, and 
MCI to AD [84, 85]; (2) higher Aβ load is associated with reduced CTh, but with subtle 
impairment of cognition in the CN and MCI stage [15, 86-94]; (3) E4+ status is 
associated with an earlier age of onset of Aβ positivity and of AD, greater Aβ levels in 
the brain, reduced hippocampal volumes and CTh in limbic and neocortical regions, and 
subtle cognitive deficits in CN individuals [23, 24, 57, 95-103]; (4) further, irrespective 
of APOE4 status, reduced hippocampal volumes and CTh in various brain regions, 
especially those regions characterized as AD signature regions, are associated with 
impaired memory and general cognition, as well as a greater risk for progression from 
CN to MCI and MCI to AD [104]. However, there is currently no consensus regarding 
the extent to which Aβ load status and APOE4 status, independently and in combination, 
are associated with neurodegenerative changes in AD prone regions and with cognitive 
impairment.  
It is important to note that both trophic and toxic effects of Aβ peptide are known and 
they may not necessarily be mutually exclusive. The toxic effects may be mediated by 
different mechanisms, such as oxidative stress, inflammation, mitochondrial diffusion, 
alterations in membrane permeability, synaptic dysfunction, and excitotoxicity through 
its interaction with neurotransmitter receptors. These effects contribute significantly to 
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the neuronal damage seen in AD, which may be associated with Aβ itself, including high 
concentrations in fibrillar or aggregated states, interaction with free metals, interactions 
with previously injured or aged brain tissue and with decreased antioxidative mechanisms 
[105-108]. 
We devised our analytic strategy to investigate, among 906 participants in the ADNI-
1/ADNI-Go and ADNI-2 cohorts, the unique and independent contributions of those 
elements, which are considered as upstream factors (i.e., Aβ load status and APOE4 
status), on downstream factors (regional CTh and cognitive measures tapping memory 
and general cognition). We also investigated the individual and additive effects of E4+ 
and Amy+ status on CTh and cognitive performance, in the earliest stages of 
neurodegeneration, using different combinations of APOE4 status and Aβ load status 
(E4-/Amy-, E4+/Amy-, E4-/Amy+ and E4+/Amy+) among CN and EMCI participants.  
Our results confirmed previous reports showing that E4+ status is associated with 
increased Aβ load among all stages of AD (Table 11). Amy+ status, among all 
participants, was found to be associated with reduced CTh in many AD vulnerable 
regions, independent of the effects of E4+ status (Table 12) [89, 90, 109, 110], but E4+ 
status was associated with reduced CTh in restricted brain regions, and only among 
LMCI and AD participants (Table 13). Unexpectedly, E4+ status was associated with 
increased CTh in some of the most vulnerable brain regions to AD pathology (i.e., the 
ERC, PHG and ITG) in the preclinical and very early stages of AD (i.e., among CN and 
EMCI participants) (Table 14).  
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Even though we found there was no observed cortical thinning in association with Amy+ 
status, and there was cortical thickening in association with E4+ status, among CN and 
EMCI participants, there was impairment on all cognitive tests among these participants, 
in association with either Amy+ and E4+ status, independently and to the greatest extent 
with combined Amy+ and E4+ status (Table 15). Global cognitive scores (ADAS13), 
among CN and EMCI participants, were significantly impaired among E4+/Amy+ groups 
as compared to all other groups, including those who were E4+/Amy-, suggesting that the 
presence of Amy+ status is independently associated with greater impairment of global 
cognitive scores. Further, memory impairment, on the RAVLT immediate test, was 
greater among those who were E4-/Amy+, as compared to those who were E4+/Amy+, 
suggesting that the presence of E4+ status is independently associated with greater 
immediate memory impairment. These results demonstrate that in the earliest stages of 
AD, in the absence of cortical thinning, there is impairment in cognitive performance 
attributable to combined E4+ and Amy+ status, as well as independently to E4+ status 
and to Amy+ status. Given that there is a known relationship between CTh and cognitive 
scores [104, 111, 112], the finding among CN and EMCI participants, who are E4+, of an 
association with increased CTh in the most vulnerable regions to AD pathology, suggests 
that the mechanism underlying neurodegeneration associated with E4+ status is distinct 
from that of Amy+ status.    
Biological processes, such as metabolic activation, increased blood flow and 
inflammation [113, 114], may result in increased volume of the cortical ribbon in brain 
regions, in which the neurodegenerative process begins, with subsequent cortical thinning 
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as neurodegeneration becomes more advanced [115-117]. It is apparent that APOE4 is a 
contributing factor to neurodegeneration, and is strongly linked to AD pathology, alone 
and particularly in combination with the Aβ peptide. APOE4 may increase Aβ deposition 
in plaques and impair its clearance, and also may act independently through pathways 
that may not involve Aβ [118]. The pathophysiological effects of APOE4 may be 
mediated at a molecular level in the process of redistribution of lipids in normal lipid 
homeostasis, repairing injured neurons, maintaining synapto-dendritic connections, and 
scavenging toxins. These pathophysiological effects result in adverse outcomes in various 
neurological conditions and in “normal” aging. E4+ status is associated with adverse 
outcomes, acceleration of progression, worsening overall prognosis in response to head 
injury, oxidative stress, ischemia, and inflammation, as well as lowering of the age of 
onset of neurodegenerative disease [115].  
A weakness of this study is that it is cross-sectional and so any inferences about 
progression from the CN to AD stage must be considered tentative. A major strength of 
the current investigation is that it utilizes a well-characterized ADNI cohort, including 
large numbers of subjects who are cognitively normal or in the earliest stages of disease, 
to power the analyses. These large numbers of subjects that are available in the ADNI 
cohort provide the statistical power required to tease apart independent effects of 
upstream biological processes, such as Aβ load and APOE4 status as they relate to 
downstream effects on CTh and cognition. Future analyses should attempt to confirm 
these findings using longitudinal analyses of the data, and to further evaluate the effects 
of regional, rather than global deposition of Aβ, on CTh and cognition. 
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In conclusion, our findings suggest that both Aβ load and APOE4 status are highly 
associated with progressive neurodegeneration, as measured by cortical thinning, 
especially in the LMCI and AD stages, and especially in brain regions which are 
vulnerable to AD pathology. Even though there is no significant cortical thinning noted in 
CN and EMCI stages, associated with E4+ or Amy+ status, there is measurable cognitive 
impairment present. The association of E4+ status with cortical thickening, rather than 
thinning, suggests the possibility of a very different pathophysiological role for E4+ from 
that of Aβ deposition in the progression of AD. 
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CHAPTER V 
DIVERGING ASSOCIATION PATTERNS OF REGIONAL CORTICAL 
ATROPHY WITH GLOBAL AND WITH REGIONAL AMYLOID DEPOSITION 
5.1. Goal 
Previous studies that have examined the effects among Aβ deposition and gray matter 
atrophy were either based on the mean global neocortical Aβ ratio or on the voxel-to-
voxel level [119-127]. The mean global neocortical Aβ ratio method classified 
individuals into Aβ normal level (Aβ negative) and Aβ abnormal level (Aβ positive), and 
compared the regional brain atrophy of those two groups within or across different 
disease stages. Nevertheless, this global way might overlook the direct assessment of 
brain amyloidosis and neurofibrillary pathology in specific regions. Although the voxel-
based approach is simple and a direct way to assess the relationship of the brain atrophy 
and Aβ load in each voxel, regional information is often ignored in many studies. 
In the present investigation, we aimed to assess and compare the association patterns of 
regional and global Aβ load with brain atrophy in AD-vulnerable and AD-unrelated 
regions, across difference stages of the disease (CN, EMCI, LMCI and AD), considering 
the mediated performance of APOE4. We further explored the relationship of global Aβ 
load and regional Aβ deposition in regions that showed different association patterns. 
Specifically, we tested the following hypotheses: (i) the association patterns with brain 
atrophy is more robust for regional Aβ load than for global Aβ load; (ii) the relationship 
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between Aβ load and brain atrophy is region-specific and disease-stage-specific; and (iii) 
regional Aβ accumulation is not always linearly related to the global Aβ load.  
5.2. Materials and Methods 
5.2.1. Study Participants 
Data and image processing method used in the preparation of this article is same as in the 
chapter II. 
5.2.2. Regions of Interest 
In this study, we tested 12 relatively vulnerable AD-related neurodegeneration regions in 
both hemispheres: entorhinal, temporal pole, parahippocampal, fusiform, inferior 
temporal, precuneus, posterior cingulate, isthmus cingulate, inferior parietal, 
supramarginal, rostral middle frontal, and insula. For contrasting purposes, we also 
considered 4 relatively resistant regions: precentral, postcentral, pericalcarine, and 
cuneus.  
5.2.3. Statistical analysis 
To compare subjects’ characteristics among the diagnostic stages: CN, EMCI, LMCI and 
AD, we performed analysis of variance (ANOVA) test on age, year of education, MMSE 
score, and CDRSB score, as well as the Chi-square test on gender and APOE4 gene. 
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Considering the mediated performance of APOE4 on the aggregated forms of Aβ [24] 
and on the cortical atrophy [128], we performed Pearson partial correlation (PPC) method 
to assess the relationship between regional/global Aβ load and regional cortical atrophy 
within each diagnostic group, controlling for the number of APOE4 alleles, age, and the 
total intracranial volume (ICV). Multiple-comparison corrections were then considered 
by controlling false discovery rate (FDR) per diagnostic group. As a secondary analysis, 
we used ANOVA method to examine whether the regional/global Aβ load or the regional 
volume was different across the spectrum of disease. Following a statistically significant 
F-test, the post hoc Tukey HSD procedure was then employed for subgroup comparisons. 
To investigate whether the relationship between regional and global Aβ accumulation is 
linear or assumed a more non-linear function, we introduced the LOESS regression 
model to fit the curve of the Aβ load in a specific region and in the whole cortical among 
all participants. In this study, the quadratic model and the smooth parameter were 
considered. 
All statistical analyses were performed using R software (R 3.3.0), a well known software 
environment for statistical computing and graphics [83].  The default significant level 
was determined as 0.05. 
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5.2.3.1. Pearson Partial Correlation (PPC) 
Pearson Partial Correlation is a measure of the linear relationship between two 
continuous variables controlling for the effect of on ore more other variables. The partial 
correlation coefficient represents the strength and direction of such relation.  
Take the right precuneus cortical region in EMCI group for example. Let xi, yi, zi1, zi2, zi3 , 
be the volume, the SUVR of such region, the number of APOE4 alleles, age and the ICV 
of patient i, (i = 1, 2, 3, ... , 296), respectively. First of all, the linear regression model for x or y and three covariance z1, z2, z3 is built (5.1), from which the fitted values xˆi  and yˆi , 
as well as the residuals !xi , !yi are calculated.  
 
xˆ =α + β1z1 + β2z2 + β3z3
yˆ =ω + γ 1z1 + γ 2z2 + γ 3z3
          (5.1) 
 
The PPC between x and y controlling for z1, z2, and z3 (rxy|z) is the Pearson correlation 
(5.2) between the residuals of the x and y after regression on z1, z2, z3. 
rxy|z =
!xi − µ !x( ) !yi − µ !y( )
i=1
296
∑
!xi − µ !x( )2
i=1
296
∑ !yi − µ !y( )2
i=1
296
∑
        (5.2) 
where, µ !x =
1
296 !xii=1
296
∑  and similarly to µ !y .  
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5.2.3.2 Locally Weighted Scatterplot Smoothing (LOESS) Regression 
The LOESS is the local polynomial regression and nonparametric method. It fits simple 
polynomial models to localized subsets of the data point by point. The number of points 
considered in each subset is defined by the smoothing parameter α , i.e., the proportion 
of data that is considered to be neighboring that point. Suppose the data size is n, at each 
point, at say x , the polynomial Y = Xβ  is fitted using weighted lease squares (5.3), i.e., 
giving more weight to points near x , and less weight to points far away. 
βˆ = XTWX( )−1 XTWY      (5.3) 
where, tricubic weighting (5.5) is used. 
W =
w1 0 0 0
0 w2 0 0
0 0 ! 0
0 0 0 wk
⎡
⎣
⎢
⎢
⎢
⎢
⎢
⎤
⎦
⎥
⎥
⎥
⎥
⎥
                    
 (5.4) 
wi = 1−
xi − x
2
j=1
k
Max xj − x 2
⎡
⎣
⎢
⎢
⎢
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⎤
⎦
⎥
⎥
⎥
⎥
3⎡
⎣
⎢
⎢
⎢
⎢
⎤
⎦
⎥
⎥
⎥
⎥
3
  
 (5.5) 
where k = nα . 
The LOESS Curve is then created based on regression function values that have been 
computed for each of the n points. In short, the LOESS combines n linear least square 
regression models in a k-nearest-neighbor-based-meta mode.  
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5.3. Results 
As indicated in Table 4 in Chapter II, significant demographic differences was found only 
for age. The presence of APOE4 was expectedly highest in AD patients, and 
intermediated in EMCI and LMCI groups. What follows are the main findings of this 
study detailed in three sections which express (1) the associations of cortical atrophy with 
global Aβ load, (2) the associations of cortical atrophy with regional Aβ load, and (3) the 
relationship between regional and global Aβ load. 
5.3.1. Associations of cortical atrophy with global Aβ load 
As expected, in AD-vulnerable regions, there was considerable negative correlation 
between the whole brain Aβ load and the cortical volume, i.e., higher Aβ deposition is 
associated with greater cortical atrophy, which was detected in AD and its prodromal 
stages of EMCI and LMCI, whereas no significant relationship was found in the CN 
stage (Figure 12A and Table 16). Specifically, inferior parietal (p = 0.004), isthmus 
cingulate (p = 0.021) in the left hemisphere and supramarginal (p = 0.008), 
parahippocampal (p = 0.025), isthmus cingulate (p = 0.025), insula (0.026), precuneus 
(0.035) in right hemisphere started to show minor but statistically significant negative 
patterns in the EMCI stage, with partial correlation coefficients r in range -0.123 to -0.17. 
The inferior parietal (left: p = 0.038, right: p = 0.009), precuneus (left: p = 0.028, right: p 
= 0.010), fusiform (left: p = 0.033, right: p = 0.003), and insula (left: p = 0.019, right: p = 
0.020) persisted with or were even strengthened in the LMCI stage.  
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In addition, similar patterns extended to the following regions in LMCI stage: entorhinal 
(left: p = 0.024, right: p = 0.019), inferior temporal and posterior cingulate (significant in 
left: p = 0.001 and 0.002, mild in right: p = 0.099 and 0.0504, respectively), left 
supramarginal (p = 0.003) and left temporal pole (p = 0.044). The range of the partial 
correlation coefficient in the LMCI stage was from -0.146 to -0.24. In AD stage, such 
pattern remained in bilateral inferior temporal (left: p= 0.037, right: p = 0.01), inferior 
parietal (left: p <0.001, right: p = 0.003), right isthmus cingulate (p = 0.022), and left 
precuneus (0.042), extending to rostral middle frontal (left: p = 0.01, right: p = 0.012).  
No significant pattern was discovered in any AD-resistant regions except for left cuneus, 
in which negative relationship was shown in AD stage  (p = 0.031).  All associations 
were mild and generally not significant after correction for multiple comparisons 
(corrected for PPC 32 tests), and the associations that remained significant was in left 
inferior temporal, left posterior cingulate, left supramarginal and right fusiform in LMCI 
stage and in bilateral inferior parietal cortex in AD stage (Table 17). 
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Fig. 12. Association patterns of cortical atrophy with global Aβ load (A), and regional Aβ load (B), 
displayed as heatmap with partial correlation coefficients displayed at p(uncorrected) < 0.05. 
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Table 16. Associations of cortical atrophy and global Aβ load 
Region CN EMCI LMCI AD 
lh_entorhinala -0.073(0.251)b -0.057(0.329) -0.164(0.024)  0.071(0.38) 
lh_temporalpole -0.035(0.588)  0.015(0.802) -0.146(0.044)  0.087(0.28) 
lh_parahippocampal -0.081(0.205) -0.105(0.073) -0.087(0.232) -0.141(0.08) 
lh_fusiform  0.004(0.945) -0.056(0.339) -0.155(0.033) -0.155(0.053) 
lh_inferiortemporal -0.109(0.088) -0.075(0.201) -0.24(0.001) -0.167(0.037) 
lh_precuneus  0.038(0.554) -0.092(0.114) -0.16(0.028) -0.163(0.042) 
lh_posteriorcingulate -0.031(0.626) -0.083(0.156) -0.229(0.002) -0.113(0.16) 
lh_isthmuscingulate  0.028(0.659) -0.135(0.02) -0.064(0.381) -0.102(0.205) 
lh_inferiorparietal  0.054(0.401) -0.17(0.004) -0.151(0.038) -0.319(0) 
lh_supramarginal  0.106(0.096) -0.065(0.27) -0.211(0.003) -0.028(0.727) 
lh_rostralmiddlefrontal -0.005(0.94) -0.086(0.142) -0.043(0.557) -0.205(0.01) 
lh_insula  0.013(0.835) -0.072(0.218) -0.17(0.019) -0.035(0.662) 
lh_cuneus  0.077(0.23)  0.052(0.372)  0.049(0.5) -0.173(0.03) 
lh_pericalcarine  0.033(0.603)  0.08(0.172)  0.03(0.678) -0.129(0.108) 
lh_postcentral  0.03(0.636)  0.021(0.716) -0.043(0.553) -0.114(0.158) 
lh_precentral  0.074(0.249)  0.063(0.284)  0.017(0.815) -0.009(0.915) 
rh_entorhinal -0.091(0.156) -0.085(0.146) -0.171(0.019)  0.047(0.563) 
rh_temporalpole  0.005(0.94) -0.083(0.156) -0.108(0.138)  0.135(0.092) 
rh_parahippocampal  0.105(0.101) -0.131(0.025) -0.132(0.069) -0.126(0.118) 
rh_fusiform -0.008(0.902) -0.102(0.082) -0.212(0.003) -0.103(0.202) 
rh_inferiortemporal -0.069(0.278) -0.08(0.17) -0.12(0.099) -0.206(0.01) 
rh_precuneus -0.037(0.565) -0.123(0.035) -0.188(0.01) -0.127(0.113) 
rh_posteriorcingulate  0.011(0.859) 0.012(0.835) -0.142(0.05)  0.071(0.376) 
rh_isthmuscingulate  0.023(0.719) -0.13(0.026)  0.01(0.892) -0.184(0.022) 
rh_inferiorparietal -0.017(0.787) -0.098(0.092) -0.19(0.009) -0.237(0.003) 
rh_supramarginal  0.112(0.079) -0.154(0.008) -0.06(0.414) -0.023(0.78) 
rh_rostralmiddlefrontal -0.057(0.369) -0.067(0.254)  0.036(0.62) -0.201(0.012) 
rh_insula  0.036(0.572) -0.13(0.026) -0.168(0.02)  0.061(0.453) 
rh_cuneus  0.108(0.089) -0.03(0.607)  0.065(0.371) -0.077(0.34) 
rh_pericalcarine  0.113(0.077)  0.065(0.266) -0.064(0.38) -0.136(0.09) 
rh_postcentral  0.096(0.133) -0.001(0.985) -0.005(0.948) -0.048(0.551) 
rh_precentral  0.091(0.154)  0.032(0.59)  0(0.996)  0.062(0.444) 
a lh=left hemisphere; rh = right hemisphere 
 
b Values are represented as Pearson Partial Correlation coefficient (uncorrected p value), with age, 
number of APOE4 and ICV as covariance. Tests significant at p<0.05 are printed in bold. 
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Table 17. Associations of cortical atrophy and global Aβ load (corrected p value) 
Region CN EMCI LMCI AD 
lh_entorhinala -0.073(0.617)b -0.057(0.434) -0.164(0.077) 0.071(0.506) 
lh_temporalpole -0.035(0.878) 0.015(0.855) -0.146(0.1) 0.087(0.426) 
lh_parahippocampal -0.081(0.617) -0.105(0.291) -0.087(0.392) -0.141(0.227) 
lh_fusiform 0.004(0.945) -0.056(0.434) -0.155(0.088) -0.155(0.171) 
lh_inferiortemporal -0.109(0.537) -0.075(0.357) -0.24(0.024) -0.167(0.148) 
lh_precuneus 0.038(0.878) -0.092(0.324) -0.16(0.081) -0.163(0.148) 
lh_posteriorcingulate -0.031(0.878) -0.083(0.324) -0.229(0.024) -0.113(0.284) 
lh_isthmuscingulate 0.028(0.878) -0.135(0.14) -0.064(0.554) -0.102(0.328) 
lh_inferiorparietal 0.054(0.802) -0.17(0.112) -0.151(0.094) -0.319(0) 
lh_supramarginal 0.106(0.537) -0.065(0.393) -0.211(0.027) -0.028(0.775) 
lh_rostralmiddlefrontal -0.005(0.945) -0.086(0.324) -0.043(0.686) -0.205(0.077) 
lh_insula 0.013(0.945) -0.072(0.367) -0.17(0.072) -0.035(0.73) 
lh_cuneus 0.077(0.617) 0.052(0.458) 0.049(0.667) -0.173(0.139) 
lh_pericalcarine 0.033(0.878) 0.08(0.324) 0.03(0.775) -0.129(0.236) 
lh_postcentral 0.03(0.878) 0.021(0.79) -0.043(0.686) -0.114(0.284) 
lh_precentral 0.074(0.617) 0.063(0.396) 0.017(0.899) -0.009(0.915) 
rh_entorhinal -0.091(0.554) -0.085(0.324) -0.171(0.072) 0.047(0.643) 
rh_temporalpole 0.005(0.945) -0.083(0.324) -0.108(0.244) 0.135(0.227) 
rh_parahippocampal 0.105(0.537) -0.131(0.14) -0.132(0.138) -0.126(0.236) 
rh_fusiform -0.008(0.945) -0.102(0.292) -0.212(0.027) -0.103(0.328) 
rh_inferiortemporal -0.069(0.636) -0.08(0.324) -0.12(0.186) -0.206(0.077) 
rh_precuneus -0.037(0.878) -0.123(0.161) -0.188(0.051) -0.127(0.236) 
rh_posteriorcingulate 0.011(0.945) 0.012(0.862) -0.142(0.108) 0.071(0.506) 
rh_isthmuscingulate 0.023(0.921) -0.13(0.14) 0.01(0.952) -0.184(0.116) 
rh_inferiorparietal -0.017(0.945) -0.098(0.296) -0.19(0.051) -0.237(0.046) 
rh_supramarginal 0.112(0.537) -0.154(0.131) -0.06(0.576) -0.023(0.805) 
rh_rostralmiddlefrontal -0.057(0.788) -0.067(0.393) 0.036(0.735) -0.201(0.077) 
rh_insula 0.036(0.878) -0.13(0.14) -0.168(0.072) 0.061(0.557) 
rh_cuneus 0.108(0.537) -0.03(0.693) 0.065(0.554) -0.077(0.495) 
rh_pericalcarine 0.113(0.537) 0.065(0.393) -0.064(0.554) -0.136(0.227) 
rh_postcentral 0.096(0.554) -0.001(0.985) -0.005(0.979) -0.048(0.643) 
rh_precentral 0.091(0.554) 0.032(0.693) 0(0.996) 0.062(0.557) 
a lh=left hemisphere; rh = right hemisphere 
 
b Values are represented as Pearson Partial Correlation coefficient (corrected p value per diagnostic 
group using FDR), with age, number of APOE4 and ICV as covariance. Tests significant at p<0.05 are 
printed in bold. 
 
 
5.3.2. Associations of cortical atrophy with regional Aβ load 
In general, compared with the global Aβ, 17 out of 32 regions of interest (ROI) showed 
exactly the same patterns in the regional Aβ level (4.3.2.1); 6 out of 32 ROIs showed 
similar patterns as in global Aβ, while extended to other diagnostic stages (4.3.2.2); 4 of 
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the 32 ROIs did not show the significant negative associations either in the regional level 
or in global level (4.3.2.3); and 5 ROIs showed unexpectedly reversed patterns, which 
was generally negative in global level, but positive in regional level (4.3.2.4). 
5.3.2.1. Regions showing same patterns with global Aβ 
Compared with the global Aβ, 17 out of 32 regions of interest (ROI) showed exactly the 
same but generally stronger patterns in the regional Aβ level. Among these 17 ROIs, 
negative correlation was detected in 9 ROIs: bilateral fusiform (left: p = 0.021, right: p < 
0.001 in LMCI), left inferior parietal (p = 0.002, 0.015, <0.001 in EMCI, LMCI and AD 
respectively), right precuneus (p = 0.023 and 0.004 in EMCI and LMCI, respectively), 
bilateral rostral middle frontal (left: p <0.001, right: p = 0.002 in AD) and right insula (p 
= 0.013, 0.016 in EMCI and LMCI, respectively), bilateral supramarginal (left: p = 0.005 
in LMCI, right: p = 0.028 in EMCI). On the other hand, there was no significant 
relationship detected in any of the prodromal stages in the following 8 ROIs: left 
parahippocampal, bilateral precentral, bilateral postcentral, bilateral pericalcarine, as well 
as right cuneus (Fig. 12B and Table 18).  
Taking insight into the right precuneus ROI, for example, similar association patterns can 
also be found from the linear regression models of volume and regional (Fig. 13A), as 
well as global  (Fig. 13B), Aβ load. Both regional and global Aβ deposition showed 
significant negative associations with volume in EMCI (p = 0.012 and 0.007, 
respectively) and LMCI stages (p = 0.033 and 0.048, respectively), and also in AD stage 
for global Aβ load (p = 0.027).  
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Table 18. Associations of cortical atrophy and regional Aβ load 
Region CN EMCI LMCI AD 
lh_entorhinala  0.078(0.22)b  0.087(0.138)  0.033(0.651)  0.247(0.002) 
lh_temporalpole  0.092(0.152)  0.132(0.024)  0.01(0.894)  0.293(0) 
lh_parahippocampal -0.004(0.954) -0.093(0.113) -0.027(0.71) -0.136(0.091) 
lh_fusiform -0.01(0.874) -0.102(0.081) -0.167(0.021) -0.136(0.089) 
lh_inferiortemporal -0.128(0.044) -0.187(0.001) -0.235(0.001) -0.203(0.011) 
lh_precuneus  0.03(0.639) -0.117(0.046) -0.17(0.019) -0.143(0.076) 
lh_posteriorcingulate -0.092(0.148) -0.151(0.01) -0.301(0) -0.163(0.042) 
lh_isthmuscingulate -0.006(0.931) -0.111(0.057) -0.102(0.163)  0.013(0.872) 
lh_inferiorparietal  0.04(0.526) -0.185(0.002) -0.176(0.015) -0.318(0) 
lh_supramarginal  0.068(0.284) -0.062(0.292) -0.204(0.005)  0.02(0.808) 
lh_rostralmiddlefrontal -0.032(0.62) -0.1(0.087) -0.07(0.336) -0.292(0) 
lh_insula  0.02(0.761) -0.121(0.038) -0.182(0.012) -0.032(0.696) 
lh_cuneus -0.006(0.929)  0.012(0.845)  0.018(0.804) -0.106(0.189) 
lh_pericalcarine  0.001(0.99)  0.024(0.687) -0.056(0.442) -0.116(0.148) 
lh_postcentral  0.01(0.869)  0.072(0.219) -0.045(0.534) -0.116(0.148) 
lh_precentral  0.084(0.187)  0.043(0.461)  0.027(0.71) -0.032(0.692) 
rh_entorhinal -0.102(0.111)  0.117(0.045)  0.056(0.442)  0.24(0.003) 
rh_temporalpole  0.036(0.572)  0.144(0.013)  0.11(0.13)  0.272(0.001) 
rh_parahippocampal  0.152(0.017) -0.043(0.462) -0.105(0.15)  0.044(0.589) 
rh_fusiform -0.06(0.347) -0.108(0.064) -0.265(0) -0.127(0.114) 
rh_inferiortemporal -0.132(0.039) -0.09(0.124) -0.129(0.076) -0.302(0) 
rh_precuneus -0.06(0.351) -0.132(0.023) -0.208(0.004) -0.118(0.143) 
rh_posteriorcingulate -0.062(0.333) -0.065(0.264) -0.232(0.001)  0.035(0.668) 
rh_isthmuscingulate -0.038(0.554) -0.219(0) -0.024(0.745) -0.063(0.435) 
rh_inferiorparietal -0.045(0.479) -0.122(0.037) -0.202(0.005) -0.224(0.005) 
rh_supramarginal  0.092(0.148) -0.128(0.028) -0.069(0.344) -0.026(0.747) 
rh_rostralmiddlefrontal -0.083(0.195) -0.08(0.17) -0.005(0.942) -0.25(0.002) 
rh_insula  0.017(0.785) -0.145(0.013) -0.174(0.016)  0.063(0.436) 
rh_cuneus  0.054(0.396) -0.024(0.68)  0.02(0.788) -0.011(0.889) 
rh_pericalcarine  0.06(0.35)  0.062(0.293) -0.114(0.117) -0.055(0.492) 
rh_postcentral  0.057(0.373) -0.007(0.9)  0.003(0.965) -0.026(0.745) 
rh_precentral  0.112(0.079)  0.001(0.992) -0.006(0.937)  0.063(0.434) 
a lh=left hemisphere; rh = right hemisphere 
 
b Values are represented as Pearson Partial Correlation coefficient (uncorrected p value), with age, 
number of APOE4 and ICV as covariance. Tests significant at p<0.05 are printed in bold. Tests 
significant at p < 0.05 and with positive partial correlation coefficient are printed in bold and italic. 
 
The performance of the Aβ load in right precuneus (Fig. 13D) was consistent with that of 
the global Aβ burden (Fig. 13E): significant increased Aβ accumulation compared with 
previous diagnostic stages, i.e. EMCI vs. CN, LMCI vs. CN and EMCI, as well as AD vs. 
CN, EMCI and LMCI, which further confirmed the aforementioned same association 
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patterns. In terms of the cortical atrophy (Fig. 13C), LMCI and AD patients showed 
significant decreased cortical volume compared to EMCI and to CN, EMCI and LMCI, 
respectively (all p < 0.001). Such cortical thinning was not detected when comparing 
EMCI to CN. However, EMCI patients showed larger cortical volume (p < 0.001), which 
was still significant after correcting for age (p = 0.004). 
5.3.2.2 Regions with stronger relations  
Six out of 32 ROIs showed similar patterns as in global Aβ, which extended to other 
diagnostic stages. Compared with the global Aβ (r = -0.24, -0.167 in LMCI and AD, 
respectively), left inferior temporal showed similar negative patterns in LMCI (r = -
0.239, p = 0.001) and stronger in AD (r = -0.203, p = 0.011), and extended such trend to 
CN (p = 0.045) and EMCI (p = 0.001) as well. Similar to left posterior cingulate (stronger 
pattern in LMCI (r = -0.301 vs. -0.229 in global), extended to EMCI and AD with p 
<0.001, =0.010, 0.042 in LMCI, EMCI and AD, respectively), left insular (mild stronger 
pattern in LMCI (r = -0.182 vs. -0.17), and extended to EMCI with p = 0.012 and 0.028, 
respectively), left precuneus (similar pattern in LMCI, mild trend in AD, and extended to 
EMCI with p = 0.019, 0.076, 0.046, respectively), right inferior temporal (stronger 
pattern in AD (r = -0.302 vs. -0.206), mild trend in LMCI, and extended to CN with p 
<0.001, = 0.076, 0.039, respectively), and right inferior parietal (similar patterns in LMCI 
and AD, extended to EMCI with p = 0.005, 0.005, 0.037, respectively). 
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Fig. 13. Linear regression models and performance of volume, regional Aβ load and global Aβ load in right 
precuneus. (A) Scatterplot of the regional Aβ load and volume. The fitted lines are from linear regression 
models for each diagnosis stage, with formulas listed at the right bottom as well as the p values for regional 
Aβ standardized uptake value ratio (SUVR) in the linear regression models. (B) Scatterplot and the linear 
regression models of global Aβ load and regional volume. (C) Boxplot of volumes across all diagnostic 
stages: CN, EMCI, LMCI and AD. C, E, and L above the boxes represented a significant difference in the 
volume from CN, EMCI, LMCI group, respectively along with the significant level: *p < .05; **p<  .01; 
***p < .001. Values in the box indicated the mean volume change rate from the previous stage (5.19% in 
the EMCI box denotes that on average, the volume in the EMCI group is 5.19% larger than that in CN 
group.) (D) Boxplot of regional Aβ load across 4 diagnostic stages, represented by the regional Aβ SUVR. 
(E) Boxplot of global Aβ load across 4 diagnostic stages, represented by the whole cortical Aβ SUVR. 
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5.3.2.3. Regions with weaker relationships  
Three of the 32 ROIs did not show the significant negative associations as detected in 
global level: left isthmus cingulate in EMCI (p = 0.057), left cuneus in AD (p = 0.189), 
and right isthmus cingulate in AD (p = 0.435). On the other hand, in right posterior 
cingulate ROI, the negative relationship reached significant level in LMCI (p = 0.001) 
compared to the mild trend in global level (p = 0.0504). 
 
Fig. 14. Association patterns of cortical atrophy with global amyloid load (A), and regional Aβ load (B), 
displayed as heatmap with partial correlation coefficients displayed at p(corrected) < 0.05. 
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5.3.2.4. Regions with reversed patterns 
There were 5 specific ROIs showing unexpectedly reversed patterns, which was generally 
negative in global level, but positive in regional level. Specifically, right 
parahippocampal showed positive correlation in CN group (p = 0.017), i.e., greater Aβ 
load was related to larger cortical volume; bilateral temporal pole (left: p = 0.024, 
<0.001, right: p = 0.013, 0.001) and right entorhinal (p = 0.045, 0.003) in EMCI and AD 
stages, and left entorhinal in AD (p = 0.002). Half of the significant associations 
remained significant after multiple-comparison correction (corrected for 32 PPC tests; 
Fig. 14B). 
For right parahippocampal ROI, similar positive correlation in CN group between volume 
and regional Aβ deposition was found through the linear regression model (Fig. 15A), 
along with the negative relationships in EMCI and LMCI stages between volume and 
global Aβ load (Fig. 15B). The performance of the volume was similar to the right 
precuneus ROI: LMCI and AD patients showed significant decreased cortical volume 
compared to EMCI and to CN, EMCI and LMCI, respectively (p< 0.001 for all), while 
EMCI patients had larger cortical volume than CN (p = 0.03) instead of cortical thinning 
(Fig. 15C), but such pattern was not significant anymore when adjusting for age (p = 
0.68). On the other hand, although the regional Aβ was significantly accumulated in AD 
stage compared with the other 3 stages, the LMC only showed significant higher Aβ load 
than CN, while no significant difference was found between CN and EMCI (Fig. 15D). 
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Table 19. Associations of cortical atrophy and global Aβ load (corrected p value) 
Region CN EMCI LMCI AD 
lh_entorhinala 0.078(0.641)b 0.087(0.22) 0.033(0.905) 0.247(0.009) 
lh_temporalpole 0.092(0.607) 0.132(0.097) 0.01(0.965) 0.293(0.002) 
lh_parahippocampal -0.004(0.985) -0.093(0.201) -0.027(0.909) -0.136(0.208) 
lh_fusiform -0.01(0.985) -0.102(0.162) -0.167(0.056) -0.136(0.208) 
lh_inferiortemporal -0.128(0.475) -0.187(0.016) -0.235(0.01) -0.203(0.035) 
lh_precuneus 0.03(0.852) -0.117(0.113) -0.17(0.056) -0.143(0.201) 
lh_posteriorcingulate -0.092(0.607) -0.151(0.071) -0.301(0) -0.163(0.122) 
lh_isthmuscingulate -0.006(0.985) -0.111(0.131) -0.102(0.307) 0.013(0.889) 
lh_inferiorparietal 0.04(0.832) -0.185(0.016) -0.176(0.052) -0.318(0.002) 
lh_supramarginal 0.068(0.702) -0.062(0.375) -0.204(0.024) 0.02(0.862) 
lh_rostralmiddlefrontal -0.032(0.852) -0.1(0.164) -0.07(0.579) -0.292(0.002) 
lh_insula 0.02(0.966) -0.121(0.112) -0.182(0.047) -0.032(0.824) 
lh_cuneus -0.006(0.985) 0.012(0.901) 0.018(0.918) -0.106(0.319) 
lh_pericalcarine 0.001(0.99) 0.024(0.758) -0.056(0.674) -0.116(0.263) 
lh_postcentral 0.01(0.985) 0.072(0.319) -0.045(0.776) -0.116(0.263) 
lh_precentral 0.084(0.624) 0.043(0.548) 0.027(0.909) -0.032(0.824) 
rh_entorhinal -0.102(0.607) 0.117(0.113) 0.056(0.674) 0.24(0.01) 
rh_temporalpole 0.036(0.832) 0.144(0.071) 0.11(0.277) 0.272(0.004) 
rh_parahippocampal 0.152(0.475) -0.043(0.548) -0.105(0.3) 0.044(0.785) 
rh_fusiform -0.06(0.702) -0.108(0.137) -0.265(0.003) -0.127(0.243) 
rh_inferiortemporal -0.132(0.475) -0.09(0.209) -0.129(0.188) -0.302(0.002) 
rh_precuneus -0.06(0.702) -0.132(0.097) -0.208(0.024) -0.118(0.263) 
rh_posteriorcingulate -0.062(0.702) -0.065(0.368) -0.232(0.01) 0.035(0.824) 
rh_isthmuscingulate -0.038(0.832) -0.219(0.006) -0.024(0.916) -0.063(0.635) 
rh_inferiorparietal -0.045(0.806) -0.122(0.112) -0.202(0.024) -0.224(0.018) 
rh_supramarginal 0.092(0.607) -0.128(0.1) -0.069(0.579) -0.026(0.824) 
rh_rostralmiddlefrontal -0.083(0.624) -0.08(0.26) -0.005(0.965) -0.25(0.009) 
rh_insula 0.017(0.966) -0.145(0.071) -0.174(0.052) 0.063(0.635) 
rh_cuneus 0.054(0.705) -0.024(0.758) 0.02(0.918) -0.011(0.889) 
rh_pericalcarine 0.06(0.702) 0.062(0.375) -0.114(0.268) -0.055(0.685) 
rh_postcentral 0.057(0.702) -0.007(0.929) 0.003(0.965) -0.026(0.824) 
rh_precentral 0.112(0.607) 0.001(0.992) -0.006(0.965) 0.063(0.635) 
a lh=left hemisphere; rh = right hemisphere 
 
b Values are represented as Pearson Partial Correlation coefficient (uncorrected p value), with age, 
number of APOE4 and ICV as covariance. Tests significant at p<0.05 are printed in bold. Tests 
significant at p < 0.05 and with positive partial correlation coefficient are printed in bold and italic. 
 
As for the right entorhinal ROI, according to the linear regression model without 
adjusting for age, APOE4 and ICV, significant negative association between regional Aβ 
load and volume was detected in CN group (p = 0.006), while positive association was 
found in AD group (p = 0.012). Unlike the PPC test, the positive correlation in EMCI 
group was mild but not significant (p = 0.196) (Fig. 16A). In terms of the global Aβ load, 
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significant negative association was found in CN, EMCI and LMCI stages (p = 0.026, 
0.044, 0.041, respectively) (Fig. 16B). In addition, the LMCI and AD showed 
dynamically smaller volume than the previous stages (CN, EMCI for LMCI; CN, EMCI, 
LMCI for AD, respectively, all p < 0.001), however, such atrophy trend was very slight 
and not significant in EMCI compared with CN (Fig. 16C). Moreover, only AD group 
showed significant higher Aβ deposition than its previous stages: CN, EMCI, and LMCI 
(p = 0.002, 0.024, 0.049, respectively). 
5.3.3. Relationship between regional and global Aβ load 
Based on aforementioned different association patterns between the regional and global 
Aβ level, we further investigated the LOESS curve of right entorhinal, right temporal 
pole, right parahippocampal ROIs, which showed opposite patterns. We also evaluated 
the fitted LOESS curve of left inferior temporal, right precuneus and left inferior parietal 
ROIs that presented consistent or even more robust negative patterns. The regional Aβ 
load in all the three ROIs with reverse patterns showed non-linearly interaction with 
global Aβ retention: the regional Aβ SUVR of right entorhinal experienced an increase 
when the global Aβ SUVR was less than 1.12, while such increasing rate was slowed 
down after the global Aβ SUVR reached 1.12. A similar but mild pattern was found in 
the left temporal pole and right parahippocampal. For those ROIs with consistent 
association patterns, the regional Aβ SUVR seemed linearly related to the global Aβ 
SUVR, since the LOESS curve was almost straight (Fig. 17).  
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Fig. 15. Linear regression models and performance of volume, regional Aβ load and global Aβ load in right 
parahippocampal. (A) Scatterplot of the regional Aβ load and volume. The fitted lines are from linear 
regression models for each diagnosis stage, with formulas listed at the right bottom as well as the p values 
for regional Aβ standardized uptake value ration (SUVR) in the linear regression models. (B) Scatterplot 
and the linear regression models of global Aβ load and regional volume. (C) Boxplot of volumes across all 
diagnostic stages: CN, EMCI, LMCI and AD. C, E, and L above the boxes represented a significant 
difference in the volume from CN, EMCI, LMCI group, respectively along with the significant level: *p 
< .05; **p<  .01; ***p < .001. Values in the box indicated the mean volume change rate from the previous 
stage. (D) Boxplot of regional Aβ load across 4 diagnostic stages, represented by the regional Aβ SUVR. 
(E) Boxplot of global Aβ load across 4 diagnostic stages, represented by the whole cortical Aβ SUVR. 
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Fig. 16. Linear regression models and performance of volume, regional Aβ load and global Aβ load in right 
entorhinal. (A) Scatterplot of the regional Aβ load and volume. The fitted lines are from linear regression 
models for each diagnosis stage, with formulas listed at the right bottom as well as the p values for regional 
Aβ standardized uptake value ration (SUVR) in the linear regression models. (B) Scatterplot and the linear 
regression models of global Aβ load and regional volume. (C) Boxplot of volumes across all diagnostic 
stages: CN, EMCI, LMCI and AD. C, E, and L above the boxes represented a significant difference in the 
volume from CN, EMCI, LMCI group, respectively along with the significant level: *p < .05; **p<  .01; 
***p < .001. Values in the box indicated the mean volume change rate from the previous stage. (D) 
Boxplot of regional Aβ load across 4 diagnostic stages, represented by the regional Aβ SUVR. (E) Boxplot 
of global Aβ load across 4 diagnostic stages, represented by the whole cortical Aβ SUVR. 
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In addition, the Aβ SUVR in right entorhinal (0.876 0.11, mean SD), left temporal pole 
(0.957 0.16) and in right parahippocampal (0.990 0.12) was lower than that of the global 
(1.189 0.21), as well as the left inferior temporal (1.144 0.22), right precuneus (1.283 
0.27) and left inferior parietal (1.255 0.26) ROIs. 
5.4. Discussion 
There are two major findings in this study: (i) the association patterns of regional Aβ load 
were generally consistent with and even more robust than the global Aβ load for almost 
all cortical regions, except for entorhinal, temporal pole and parahippocampal, the three 
most AD-vulnerable regions [129-132]. (ii) Aβ accumulation in those three high AD-
vulnerable regions showed sharp growth prior to the global Aβ load reaching an 
abnormal level, but the speed slowed down after that. On the other hand, in other brain 
areas, the regional Aβ load showed consistent increasing rate regardless of the global Aβ 
burden. 
The observed negative associations of cortical atrophy and global Aβ load are consistent 
with previous findings [121, 127, 133, 134]. The Aβ-related cortical atrophy was first 
detected in the EMCI stage in the following regions: parahippocampal [134], inferior 
parietal, precuneus, isthmus cingulate, supramarginal and insula, followed by entorhinal, 
temporal pole, fusiform, inferior temporal, posterior cingulate in the LMCI stage [127, 
134], and significantly presented in rostral middle frontal in the AD stage ultimately. The 
regional-specific association across diagnosis stages and the enhanced correlation of Aβ 
load with cortical atrophy in LMCI and AD stages agreed with the spatial topography of 
 77 
neurodegenerative change [79] and were also in line with the view that different brain 
areas can be at different atrophy levels regarding reactivity to Aβ burden [10]. In 
addition, only right parahippocampal showed Aβ-load-related atrophy in EMCI stage. 
Also, precuneus presented such correlation firstly in right hemisphere in EMCI stage and 
extended to left hemisphere later in the LMCI stage. Such different patterns of left and 
right hemisphere supported the view of laterality in alterations [135].  
 
Fig. 17. Associations between regional and global Aβ load. The fitted curves are from LOESS regression 
models for all subjects, with smoothing degree equals to 0.4. 
 
The inconsistent positive correlation of cortical atrophy with regional Aβ burden in right 
parahippocampal in CN stage had been reported in a previous study [136] that informed 
larger hippocampal and parahippocampal volume in CN participants with high Aβ load 
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measured by PIB PET. Such hippocampal hypertrophy in the brains of normal elderly 
with Aβ plaques compared to those without Aβ plaques had been evidenced at some 
autopsy studies and were explained as the early response to the toxic effects of Aβ 
peptide [137, 138]. Besides, the larger cortical volume in EMCI stage followed by 
cortical atrophy in LMCI and AD stages in parahippocampal (Fig. 15C) and in precuneus 
(Fig. 16C) ROIs was also agreed with the view of biphasic trajectory of brain structure 
changes as reported in [139, 140], and may also be interpreted as neuronal hypertrophy 
and/or inflammatory response to the toxic effect of Aβ peptide. 
On the other hand, the negative correlation between regional/global Aβ burden and 
regional volume in CN stage was found only in right entorhinal ROI from the linear 
regression model (Fig. 16A), which was consistent with other studies [80, 88, 129, 130, 
141] and supported the view that Aβ deposition is associated with a pattern of cortical 
atrophy prior to the development of cognitive impairment, i.e., cognitive reserve [80]. 
This finding also confirmed that the entorhinal is one of the earliest brain regions 
revealing degeneration [142]. However, when accounting for the effects of age, APOE4 
and ICV, such regional Aβ-induced cortical atrophy in right entorhinal in CN stage was 
not detectable, instead, positive association was shown in EMCI stage and later in AD 
stage. A few previous studies had also reported increased metabolic activity, which is 
another way to express neurodegeneration, in the brain measured by FDG PET in MCI 
[143, 144] and increased cerebral blood flow in AD [134] in relation to the increased Aβ 
load. Such positive association may either reflect early response to the Aβ toxic effect, or 
imply that Aβ accumulation itself results from the increased neural activity [134, 143, 
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145]. In fact, we can see from Fig. 16 that both volume and Aβ burden underwent 
significant change in AD, 13.37% atrophy compared with LMCI and 3.45% Aβ 
accumulation. Furthermore, the relatively unchanged Aβ load from CN to LMCI stage 
(1.16% form CN to EMCI and 0% form EMCI to LMCI, Fig. 4D) and the mild but not 
significant decreased volume size from CN to EMCI (-0.59%) followed by the 
dynamically volume shrinking from EMCI to LMCI (-11.42%) (Fig. 16C) inferred the 
postponed effect of Aβ load on neurodegeneration [10].  
The LOESS regression analyses of regional Aβ load and global Aβ accumulation also 
elicited the inconsistent patterns of these 3 AD prone ROIs: entorhinal, temporal pole and 
parahippocampal. Unlike other brain areas where regional Aβ accumulation was 
consistent with that in the whole cortical, Aβ in these 3 ROIs underwent dynamically 
accumulate among patients identified as Aβ negative (AM-), considering the common 
cutoff value range of 1.10 to 1.12 [81, 82, 146, 147], and relatively slower increase for 
Aβ positive (AM+) patients. In fact, these 3 ROIs are known to be selectively vulnerable 
to pathology and undergo neurodegeneration before all other brain regions when exposed 
to toxins, including Aβ. Once neurodegeneration begins in the entorhinal and the 
parahippocampal (Fig. 16C & Fig. 16C), it seems to spread, like an infection, in a 
stereotyped fashion along certain pathways leading to neurodegeneration in the 
hippocampus, and then onto the posterior cingulate/precuneus (Fig. 15C) regions and 
later to the rest of the temporal, parietal and frontal neocortex. This finding suggests that 
Aβ load in the entorhinal, temporal pole and parahippocampal is possibly the most 
important biomarkers to early detection of the disease. Also, biologically important cut 
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off for AM+ vs. AM- should not only be the global cortical Aβ SUVR, which most 
researchers are using, but entorhinal, temporal pole and parahippocampal SUVR should 
also be taken into consideration, even though their Aβ levels happen to be much lower 
than the neocortical Aβ level. 
To conclude, the present study provided strong evidence for the effect of Aβ load in 
entorhinal, temporal pole and parahippocampal on brain atrophy prior to other brain 
regions and to the global Aβ load, suggesting the use of Aβ load in these regions to assist 
early detection of AD, and to determine the Aβ positivity rather than the global Aβ load. 
Further longitudinal analysis is needed to better understand the predictive value of Aβ 
load within those AD prone regions.  
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CHAPTER VI 
PATTERN ANALYSIS OF THE INTERACTION OF REGIONAL AMYLOID, 
CORTICAL THICKNESS, AND APOE GENOTYPE IN THE PROGRESSION OF 
ALZHEIMER’S DISEASE 
6.1. Goal 
Deposition of beta amyloid protein (Aβ) is known to be an early event that is closely 
associated with the pathogenesis of Alzheimer's disease (AD), along with related 
downstream events such as neuronal loss, neurofibrillary tangles, cortical thinning and 
cognitive deficits. APOE e4 allele (E4) is also known to be associated with increased risk 
for AD. 
The goal of this study is to examine the association of Aβ deposition to cortical thickness 
(CTh), in healthy control (CN), early MCI (EMCI), late MCI (LMCI) and AD stages by 
controlling for E4 load, both in regional and hemispheric levels, and to interpret patterns 
of different brain regions based on their correlation performance among the four groups. 
6.2. Materials and Methods 
6.2.1. Study Participants 
Data and image processing method used in the preparation of this study is the same as in 
the chapter II. 
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6.2.2. Statistical analysis 
To compare the subject’s characteristics among the diagnostic groups (CN, EMCI, LMCI 
and AD), analysis of variance (ANOVA) was implemented for age as well as for year of 
education, while Chi-square test was used for gender and E4 allele. Since only the 
significant difference of age was investigated, analysis of covariance (ANCOVA) 
adjusted for age was then introduced to compare the cognitive tests (MMSE and 
RAVLT) among groups. 
Considering the mediated performance of E4 on the aggregated forms of Aβ [148], we 
used Pearson partial correlation (PPC) controlling for the number of APOE e4 alleles to 
assess the relationship between regional as well as hemispheric CTh and SUVR, which 
was then used as the performance measure of such region in the specific groups (CN, 
EMCI, LMCI or AD) later. Multiple-comparison correction was then considered across 
all PPC analyses by controlling false discovery rate (FDR). The statistical analysis was 
performed using R software (R 3.3.0) using the default significant level (p value) of 0.05. 
6.2.3. Clustering Analysis 
To interpret patterns of ROIs based on their correlation performance, the complete 
linkage hierarchical clustering analysis (CL_HCA) was applied. The CL_HCA is carried 
out through a series of successive mergers. As is shown in Fig. 18, initially, there are as 
many clusters as objects, i.e. 5 in this case. The most similar objects are first merged as a 
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group, i.e. G1 with objects a and b, and such groups are then merged according to their 
similarities. All subgroups are fused into a single cluster eventually. 
In terms of how the complete linkage clustering proceeds, the similarity between clusters 
is determined by the distance (similarity) between the two elements, one from each 
cluster, that are most distant. The complete linkage function, i.e. distance D(U,V) 
between clusters U and V, is described in (6.1). 
D U,V( ) =maxu∈U,v∈V d u,v( )     (6.1) 
where d(u,v) is the distance between u and v , which are the objects in cluster U and 
cluster V, respectively. 
 
 
Fig. 18. Complete linkage hierarchical clustering illustration: (a) similarity. The distance of new cluster G1 
and G2 is defined as d (a,c) which is the maximum distance among (a,c), (a,e), (b,c) and (b,e); (b) 
dendrogram. Object a and b are fist merged as new cluster G1, followed by object c and e (G2), then object 
d and cluster G1 were merged as new cluster, and finally merged with G2 into a single cluster. 
 84 
In the context of this study, the u and v represent the specific ROIs in each cluster, and 
the region-to-region distance d(u,v) is as defined in (6.2). 
d u,v( ) = ruCN − rvCN( )2 + ruEMCI − rvEMCI( )2 + ruLMCI − rvLMCI( )2 + ruAD − rvAD( )2   (6.2) 
where, ruCN  represents the PPC coefficient (5.2) of region u in group CN. For those not 
showing significant correlation, the PC coefficient r is set to 0. 
Both the correlation results and clustering analysis are represented using heatmaps to 
facilitate both visualization and interpretation of the results provided in the next section. 
6.3. Results 
At the regional level, 25 out of 68 ROIs presented significant correlations of SUVR and 
CTh at least in one of the four diagnostic groups (CN, EMCI, LMCI, and AD), among 
which, 9 in bilateral hemispheres (bi_), 3 in left hemisphere (lh_), and 4 in right 
hemisphere (rh_), respectively. While at the hemispheric level, both mean hemisphere 
cortical thickness showed significant negative associations to the corresponding mean Aβ 
deposition of left hemisphere but only in the EMCI stage (Fig. 19).  
In the pattern of such relationship performance among the 4 groups, 6 main clusters of 
those 25 ROIs were identified: 
• C1(negative CN+EMCI):  
o rh_inferior_temporal 
• C2 (negative EMCI): 
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o bi_fusiform, bi_precuneus, bi_superior_temporal, bi_lateral_occipital 
o lh_medialorbitofrontal, lh_isthmuscingulate  
o rh_superamarginal, rh_middle_temporal  
• C3 (negative EMCI+LMCI):  
o lh_inferior_temporal, lh_middle_temporal, 
lh_banks_of_the_Superior_semporal_sulcus (lh_bankssts)  
o rh_inferior_parietal  
• C4 (negative LMCI):  
o lh_inferior_parietal 
• C5 (positive CN):  
o rh_postcentral, rh_transversetemporal, rh_precentral 
• C6 (positive AD):  
o bi_entorhinal, bi_temporal_pole 
Specifically, ROIs in C1 exhibited steady negative significant correlation trends among 
CN and EMCI groups; C2 showed reversed correlation in EMCI stage; C3 showed such 
reversed relationship also in EMCI stage, which were maintained in the LMCI stage; C4 
showed negative correlation only in the LMCI stage. On the other hand, ROIs in C5 
presented positive significant correlation in CN stage; C6 showed such correlation in the 
AD stage. Similar associations were found even when using Pearson correlation (Fig. 20). 
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Fig. 19. Heatmap representation of clustering analysis. The PPC coefficient, i.e., r value, is shown in each 
block. 
 
The remaining 43 ROIs, which were found to be without any significant association, are 
listed below:  
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• Bilateral: bi_frontal_pole, bi_superior_frontal, bi_rostral_middle_frontal, 
bi_pars_triangularis, bi_pars_orbitalis, bi_paracentral, bi_lingual, 
bi_lateral_orbitofrontal, bi_insula bi_cadual_middle_frontal, bi_cuneus 
bi_caudal_anterior_cingulate, bi_rostral_anterior_cingulate, 
bi_posterior_cingulate, bi_superior_parietal, bi_parahippocampal, 
bi_pericalarine,  
• Left: lh_precentral, lh_postcentral, lh_superamarginal, lh_transverse_temporal  
• Right: rh_medial_orbitofrontal, rh_bankssts, rh_isthmus_cingulate 
6.4. Discussion and Conclusion 
The main findings of this study suggest that there are cortical areas that have significant 
association with Aβ deposition, while other regions seem to be relatively independent 
from Aβ burden. Also, patterns of those regions showing significant association are in 
general distinctive with regards to the different stages of the disease, with some showing 
relative similarities. Briefly, negative associations, i.e. higher Aβ deposition is associated 
with reduced cortical thickness, were detected mainly among EMCI with some lingering 
into LMCI stage; whereas positive correlations, i.e. higher Aβ deposition is related to 
higher cortical thickness were shown at the CN and AD stages. 
Three ROIs in right hemisphere showed positive correlation in CN stage, however, such 
correlation did not exist later for the EMCI and subsequent stages, which could indicate 
that the amyloid deposition in those regions increased significantly in the EMCI stage 
(Fig. 20a).  
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Fig. 20. Scatterplot, linear regression as well as boxplot of (a) right precentral, (b) left inferior 
temporal, and (c) right entorhinal. 
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Almost all ROIs showing negative association appeared in the EMCI stage, except for the 
left inferior parietal. Four of them persisted with such trend towards the LMCI stage, 
implying that both Aβ load and cortical thinning are active in MCI regions, i.e., more Aβ 
load exists in direct association with more brain atrophy [119-126](Fig. 20b). Bilateral 
entorhinal and temporal pole, which are well-known vulnerable ROIs, showed positive 
correlation in the AD stage, whereas no correlation was found in other stages, which may 
be due to greater regional atrophy and relatively stable amyloid depositions in such 
regions, i.e., the increasing rate of Aβ deposition is low compared with the greater regional 
atrophy (Fig. 20c). Also, from Fig. 20, we can see that the mean CTh of EMCI patients is 
thicker than that of CN, same as SUVR, which may also be the reason of no significant 
negative correlation being detected in such vulnerable regions as the entorhinal and 
temporal pole. 
In retrospect, the cortical regions can be clustered into 2 general groups, positive 
correlation in CN or AD, and negative correlation in EMCI and/or LMCI, and 6 more 
specific groups were then recognized, suggesting the merits of analyzing the regional 
interplay that exists between Aβ deposition with cortical thickness at the different stages 
of Alzheimer’s disease. 
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CHAPTER VII 
REGIONALSHIP BETWEEN REGIONAL CORTICAL THICKNESS, AMYLOID 
LOAD AND SELECTIVE VULNERABILITY TO ATROPHY IN ALZHEIMER’S 
DISEASE 
7.1. Goal 
CTh is known to vary greatly across different brain regions, with primary motor and 
sensory cortices being thinner than association cortices, although the effect of normal 
aging and disease may alter this relationship [149]. Thinning of the cortex between young 
and middle-aged adults was found to be greatest in heteromodal association cortex and 
regions of high postnatal surface area [150]. Some studies have shown that temporal and 
occipital regions have less cortical thinning than parietal and frontal cortices, and there 
may even be age-related thickening of the ERC among older cognitively normal 
individuals [149].  
In this study, we examined relationships between baseline regional CTh (rCThCN), 
baseline regional Aβ load (rSUVRCN) and the severity of change in CTh between CN 
subjects and AD patients (%CThDiff), with consideration of the effect of APOE4 carrier 
status and global Aβ load.  
 91 
7.2. Materials and Methods 
7.2.1. Study participants 
In this study, we focused on subjects classified as cognitively normal (CN) or AD by 
ADNI, who underwent MRI and AV45 PET scans within 6 months. Since only few CN 
individuals have progressed to AD dementia in the ADNI cohort, we matched the AD 
patients to CN subjects based on the age, gender and the APOE4 status. Subjects without 
APOE4 alleles were classified as APOE4 negative (E4-), while those with one or more 
APOE4 allele were classified as APOE4 positive (E4+). Overall, 105 CN subjects and 
105 AD patients were considered. Table 20 provides the demographic characteristics of 
the participants. 
Table 20. Age, gender-matched participants’ demographic information 
 CN AD  P valuea 
N 105 105 1 
Female/Male 45/60 45/60 1 
E4-/+ 47/58 47/58 1 
gSUVR-/+ 65/40 22/83 4.01e-09 
Age 75.22(6.95) 75.22(7) 1 
Education 16.34(2.55) 16.14(2.64) 0.5766 
CDR-SB 0.06(0.24) 4.61(1.81) <2.2e-16 
MMSE 29.06(1.14) 23.02(2.59) <2.2e-16 
a P-values are for t-test (continuous variables: Age, Education, Clinical Dementia Rating Scale Sum of 
Boxes (CDR-SB) and Mini-Mental State Examination (MMSE)) and for Chi-square test (categorical 
variables: gender, APOE genotype (E4-/E4+) and global Aβ load status (gSUVR-/gSUVR+)), The criteria 
for significance was set at level p<0.05. 
 
b Values are represented as mean(SD) for all continuous attributes 
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7.2.2. Severity of Change in Cortical Thickness Between CN and AD Patients  
Once the MRI and PET were processed as descripted in Chater II, we got the regional 
cortical thickness (rCTh), the regional amyloid load (rSUVR) and the gloal amyloid 
(gSUVR). A widely used threshold value of 1.11 is used to delineate Aβ positive 
(gSUVR+) and Aβ negative (gSUVR-) status. 
The percent difference CTh between CN and AD subjects (%CThDiff ) for those with and 
without the E4 allele was calculated using (7.1) for each of 68 brain regions separately.  
        %CThDiff = (rCThCN − rCThAD ) / rCThCN ×100     (7.1) 
where rCThCN and rCThAD are the mean CTh among CN individuals and AD patients, 
respectively. Taking the CN with E4+ group for example, the mean rCTh for a specific 
region was measured as (7.2): 
rCThCN = rCThi
i=1
NCNE 4+
∑ / NCNE+      (7.2) 
where NCNE4+ is the number of CN subjects with E4+ and rCThi is the CTh of the specific 
region for subject i.  
Similar calculations were performed for Aβ positive (gSUVR+) and Aβ negative 
(gSUVR-) subjects. 
7.2.3. Statistical analysis 
To compare subjects’ characteristics between CN and AD, a series of Student’s t-tests 
were employed for age, years of education, as well as for the cognitive tests that include 
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Mini-Mental State Examination (MMSE) and Clinical Dementia Rating-Sum of Boxes 
(CDR-SB); while the Chi-square test was used to account for gender, APOE4 status and 
global amyloid load status.  
The association between %CThDiff and rCThCN across 68 cortical regions was 
examined using the linear regression, as well as Pearson correlation, separately for E4+ 
and E4- participants. The comparative strength of the magnitude between these 
correlations was examined using the two-tailed Fisher’s z transformation.  
A similar set of procedures was applied to examine the magnitude of correlations 
between gSUVR+ and gSUVR-. 
The potential effect of rSUVRCN on the relationship between rCThCN and %CThDiff 
was evaluated by employing the Pearson Partial Correlation and multiple linear 
regression models with simultaneous adjustment of predictors, i.e. rCThCN and 
rSUVRCN.  
All statistical analyses were performed using R software (R 3.3.3) [83] and the statistical 
significance level was set at 0.05. 
7.3. Results 
As shown in Table 20, there was no significant difference between CN and AD subjects, 
with regards to age, gender, the frequency of E4+ or years of education. However, the 
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frequency of gSUVR+ was higher among AD than CN subjects. Table 21 and Table 22 
provide the mean regional CThs for the CN and AD groups, %CThDiff and the 
rSUVRCN in the left hemisphere for E4+ and E4- subjects, respectively. 
7.3.1. Associations between rCThCN and Regional %CThDiff for E4+ and E4- 
Subjects 
As can be observed from Table 23 and Fig. 21, results indicate that greater rCThCN is 
associated with greater %CThDiff, both before (r = 0.639, p-value < 0.001 for E4+; r = 
0.768, p < 0.001 for E4-) and after (r = 0.521, p < 0.001 for E4+; r = 0.694, p < 0.001 for 
E4-) adjusting for the effect of rSUVRCN.  
We compared the magnitude of the Pearson correlation coefficients for E4+ versus E4- 
groups using Fisher’s z-transformation. Results showed no difference in the magnitude of 
the correlation coefficient between the E4+ and E4- groups (z = -1.469; p = 0.142).  
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Table 21. CTh in the CN and AD Groups,  % mean differences between CN and AD groups (%CThDiff) and 
regional Aβ load (rSUVRCN), for E4+ subjects in the left hemisphere 
ROI E4+ 
rCThCN rCThAD %CThDiff  rSUVRCN 
entorhinal 3.38(.35)a 2.60(.47) 23.08% 0.89(.08) 
parahippocampal 2.69(.35) 2.31(.37) 14.13% 0.96(.11) 
temporalpole 3.58(.31) 3.11(.48) 13.13% 0.94(.14) 
middletemporal 2.71(.17) 2.44(.23) 9.96% 1.14(.21) 
superiortemporal 2.59(.19) 2.35(.19) 9.27% 1.11(.19) 
fusiform 2.62(.17) 2.38(.19) 9.16% 1.11(.15) 
inferiortemporal 2.67(.16) 2.44(.26) 8.61% 1.13(.20) 
isthmuscingulate 2.36(.22) 2.16(.20) 8.47% 1.24(.19) 
inferiorparietal 2.21(.18) 2.05(.19) 7.24% 1.23(.25) 
bankssts 2.32(.17) 2.16(.20) 6.90% 1.4(.24) 
precuneus 2.15(.17) 2.01(.15) 6.51% 1.25(.25) 
lateraloccipital 2.02(.17) 1.91(.19) 5.45% 1.17(.18) 
supramarginal 2.34(.17) 2.22(.15) 5.13% 1.19(.21) 
superiorparietal 1.99(.17) 1.89(.15) 5.03% 1.17(.21) 
insula 2.93(.17) 2.83(.18) 3.41% 1.15(.17) 
superiorfrontal 2.49(.16) 2.41(.17) 3.21% 1.15(.21) 
transversetemporal 2.19(.28) 2.12(.21) 3.20% 1.18(.20) 
caudalmiddlefrontal 2.34(.18) 2.28(.17) 2.56% 1.24(.20) 
posteriorcingulate 2.40(.19) 2.34(.17) 2.50% 1.30(.23) 
parsorbitalis 2.54(.23) 2.48(.25) 2.36% 1.09(.20) 
cuneus 1.72(.14) 1.68(.14) 2.33% 1.14(.14) 
rostralmiddlefrontal 2.15(.15) 2.1(.15) 2.33% 1.23(.25) 
medialorbitofrontal 2.28(.17) 2.23(.14) 2.19% 1.11(.22) 
lingual 1.83(.14) 1.79(.14) 2.19% 1.06(.11) 
postcentral 1.87(.17) 1.83(.14) 2.14% 1.09(.15) 
parsopercularis 2.39(.14) 2.34(.15) 2.09% 1.2(.20) 
lateralorbitofrontal 2.48(.16) 2.43(.19) 2.02% 1.19(.19) 
parstriangularis 2.23(.18) 2.19(.15) 1.79% 1.21(.22) 
precentral 2.33(.22) 2.29(.17) 1.72% 1.16(.13) 
caudalanteriorcingulate 2.74(.33) 2.71(.39) 1.09% 1.30(.21) 
rostralanteriorcingulate 2.79(.31) 2.76(.29) 1.08% 1.26(.24) 
frontalpole 2.55(.27) 2.56(.29) -0.39% 1.01(.24) 
pericalcarine 1.48(.14) 1.49(.13) -0.68% 1.27(.18) 
paracentral 2.17(.17) 2.19(.17) -0.92% 1.19(.18) 
a Values are represented as mean(sd). CTh unit: millimeter (mm). 
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Table 22. CTh in the CN and AD Groups,  % mean differences between CN and AD groups (%CThDiff) and 
regional Aβ load (rSUVRCN), for E4- subjects in the left hemisphere 
ROI E4- 
rCThCN rCThCN rCThCN rCThCN 
entorhinal 3.30(.33)a 3.30(.33) 3.30(.33) 3.30(.33) 
parahippocampal 2.62(.38) 2.62(.38) 2.62(.38) 2.62(.38) 
temporalpole 3.52(.39) 3.52(.39) 3.52(.39) 3.52(.39) 
middletemporal 2.65(.21) 2.65(.21) 2.65(.21) 2.65(.21) 
superiortemporal 2.54(.23) 2.54(.23) 2.54(.23) 2.54(.23) 
fusiform 2.55(.18) 2.55(.18) 2.55(.18) 2.55(.18) 
inferiortemporal 2.63(.16) 2.63(.16) 2.63(.16) 2.63(.16) 
isthmuscingulate 2.27(.22) 2.27(.22) 2.27(.22) 2.27(.22) 
inferiorparietal 2.18(.18) 2.18(.18) 2.18(.18) 2.18(.18) 
bankssts 2.27(.20) 2.27(.20) 2.27(.20) 2.27(.20) 
precuneus 2.12(.19) 2.12(.19) 2.12(.19) 2.12(.19) 
lateraloccipital 1.95(.15) 1.95(.15) 1.95(.15) 1.95(.15) 
supramarginal 2.27(.19) 2.27(.19) 2.27(.19) 2.27(.19) 
superiorparietal 1.96(.20) 1.96(.20) 1.96(.20) 1.96(.20) 
insula 2.93(.19) 2.93(.19) 2.93(.19) 2.93(.19) 
superiorfrontal 2.46(.20) 2.46(.20) 2.46(.20) 2.46(.20) 
transversetemporal 2.13(.26) 2.13(.26) 2.13(.26) 2.13(.26) 
caudalmiddlefrontal 2.33(.20) 2.33(.20) 2.33(.20) 2.33(.20) 
posteriorcingulate 2.40(.18) 2.40(.18) 2.40(.18) 2.40(.18) 
parsorbitalis 2.52(.23) 2.52(.23) 2.52(.23) 2.52(.23) 
cuneus 1.68(.15) 1.68(.15) 1.68(.15) 1.68(.15) 
rostralmiddlefrontal 2.16(.16) 2.16(.16) 2.16(.16) 2.16(.16) 
medialorbitofrontal 2.29(.15) 2.29(.15) 2.29(.15) 2.29(.15) 
lingual 1.82(.13) 1.82(.13) 1.82(.13) 1.82(.13) 
postcentral 1.84(.17) 1.84(.17) 1.84(.17) 1.84(.17) 
parsopercularis 2.36(.19) 2.36(.19) 2.36(.19) 2.36(.19) 
lateralorbitofrontal 2.46(.15) 2.46(.15) 2.46(.15) 2.46(.15) 
parstriangularis 2.23(.18) 2.23(.18) 2.23(.18) 2.23(.18) 
precentral 2.3(.26) 2.3(.26) 2.3(.26) 2.3(.26) 
caudalanteriorcingulate 2.63(.33) 2.63(.33) 2.63(.33) 2.63(.33) 
rostralanteriorcingulate 2.81(.28) 2.81(.28) 2.81(.28) 2.81(.28) 
frontalpole 2.6(.29) 2.6(.29) 2.6(.29) 2.6(.29) 
pericalcarine 1.47(.14) 1.47(.14) 1.47(.14) 1.47(.14) 
paracentral 2.16(.23) 2.16(.23) 2.16(.23) 2.16(.23) 
a Values are represented as mean(sd). CTh unit: millimeter (mm). 
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Fig. 21. Plot of rCThCN and %CThDiff with the estimated linear regression model for the E4+ and E4- 
groups. R is the correlation coefficient for the Pearson correlation; R_PPC is the correlation coefficient for 
the Pearson Partial Correlation, adjusting for rSUVRCN. Abbreviations: bankssts, banks of the superior 
temporal sulcus; CAC, caudal anterior cingulate; CMF, caudal middle frontal; ERC, entorhinal cortex; IP, 
inferior parietal; IT, inferior temporal; IC, isthmus cingulate; LO, lateral occipital; LOF, lateral 
orbitofrontal; MOF, medial orbitofrontal; MT, middle temporal; PHG, parahippocampal; POP, pars 
opercularis; POB, pars orbitalis; PTG, pars triangularis; PC, posterior cingulate; RAC, rostral anterior 
cingulate; RMF, rostral middle frontal; SF, superior frontal; SP, superior parietal; ST, superior temporal; 
SM, supramarginal; FP, frontal pole; TP, temporal pole; TT, transverse temporal. Except for the ERC, only 
ROIs in the left hemisphere were labeled since the similar patterns are observed in the right hemisphere. 
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Table 23. Associations of rCThCN with %CThDiff before and after separating out the effect of rSUVRCN 
 Linear Regression Modela Pearson 
Correlation 
PPCb 
Intercept rCThCN 
E4+ 
Coefficient -12.931 7.228 0.639 0.521 
Pvaluec 5.10e-06 *** 4.49e-09 *** 4.487e-09*** 6.245e-06*** 
E4- 
Coefficient -13.803 7.779 0.768 0.694 
Pvalue 7.49e-10 *** 2.25e-14 *** 2.255e-14*** 7.748e-11*** 
a Linear regression model: %CThDiff =α + βrCThrCThCN   
 
b PPC, Pearson Partial Correlation of rCThCN and regional %CThDiff, correcting for rSUVRCN 
 
c p-value: *p<.05; **p< .01; ***p< .001 
 
 
7.3.2. Effects of rCThCN and rSUVRCN on %CThDiff 
When including the interaction term rCThCN × rSUVRCN in the multiple linear regression 
model %CTh
Diff =α + βrCThrCThCN + βrSUVRrSUVRCN + βCTh⋅SUVRrCThCN × rSUVRCN , all variance 
inflation factors (VIFs) were larger than 10 (85.8/101.8, 30.4/30.2, and 69.0/81.2 for 
rCThCN, rSUVRCN, and rCThCN × rSUVRCN, and for E4+/E4-, respectively), indicating a 
very high level of multicollinearity. Thus, we excluded the interaction term in the linear 
regression study. 
As depicted in Table 24, both rCThCN and rSUVRCN were independent significant 
predictors of %CThDiff in both E4+ and E4- subjects. Specifically, standardized beta 
coefficients showed greater explanatory power for rCThCN than rSUVRCN in both E4+ 
(βrCTh=2.357, βrSUVR=-1.563) and E4- (βrCTh=2.594, βrSUVR=-1.399) groups. 
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The results shown in Fig. 22 and Table 24 reveal a negative relationship between the 
rSUVRCN and the %CThDiff, which was opposite to the rCThCN. Specifically, regions with 
the greatest %CThDiff were aggregated in regions such as ERC (23.08%/18.79%, for 
E4+/E4- group), parahippocampal gyrus (14.13%/9.92%), and temporal pole 
(13.13%/12.50%), which also had the greatest rCThCN (3.38mm/3.30mm, 
2.69mm/2.62mm, 3.58mm/3.52mm, for ERC, parahippocampal gyrus and temporal pole, 
respectively). However, these regions tended to have the lowest rSUVRCN (0.89/0.87, 
0.96/0.92, 0.94/0.88). In contrast, rCThCN was lowest in the pericalcarine, cuneus, 
postcentral, precuneus, and superior parietal regions, which also had the least %CThDiff 
but the highest rSUVRCN (Table 21 and Table 22).  
Table 24. Effects of rCThCN and rSUVRCN on %CThDiff a 
 Intercept rCThCN rSUVRCN adjust R2 
E4+ 
Coefficients 5.71 2.14b -1.53 0.458 
p-valuec < 2e-16 *** 1.36e-05 *** 0.00133 **  8.28e-10*** 
E4- 
Coefficients 4.66 2.27 -1.35 0.598 
p-value < 2e-16 *** 4.08e-08 *** 0.000445 *** 5.01e-14*** 
a Multiple regression model: %CThDiff =α + βrCThrCThCN + βrSUVRrSUVRCN  
 
b Using normalized values of rCThCN and rSUVRCN (mean = 0 and SD = 1) in the model, thus, the 
coefficient is the adjusted beta weight. 
 
c p-value: *p<.05; **p< .01; ***p< .001 
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7.3.3 Associations between rCThCN and Regional %CThDiff for gSUVR+ and 
gSUVR- Subjects 
The obtained correlation coefficients were 0.613 for the gSUVR+ group and 0.831 for the 
gSUVR- group, which showed significant difference using the Fisher’s z-test  (z = -
2.724; p =0.0065) (Fig. 23). 
7.4. Discussion 
The regional CTh has been found to vary considerably across regions in human and 
primate brains, with primary sensory cortices being thinner than motor regions, which in 
turn are thinner than association cortices [151]. Normal aging is accompanied by global 
as well as regional structural changes. Both CTh and volumetric measures have 
demonstrated that the prefrontal cortex and to a lesser extent the parietal cortex, are 
sensitive to age-related decline [149, 152, 153]. In the current study, the age-related 
change in brain atrophy was accounted for using the age-equivalent CN and the AD 
group from the ADNI sample to examine those factors that pertained to selective 
vulnerability for neurodegeneration associated with Alzheimer’s disease. 
Our main findings are that: (1) regions with the greatest CTh at the CN stage are 
aggregated in regions which have been found to be most vulnerable to neurodegeneration 
in AD, namely regions in the medial temporal lobe, including the temporal pole, ERC, 
parahippocampal gyrus, fusiform and the middle and inferior temporal gyrus; (2) regions 
with the lowest CTh in the CN stage were aggregated in regions which tend to be least 
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vulnerable to neurodegeneration, namely the pericalcarine region, cuneus and the 
postcentral gyrus; (3) %CThDiff was positively correlated to rCThCN, even after adjusting 
for the effect of rSUVRCN; (4) rCThCN showed greater explanatory power for %CThDiff 
than rSUVRCN; (5) there were no overall effect of  the APOE4 genotype on the  
association between the rCThCN and %CThDiff; (6) the global Aβ load negative patients 
showed stronger effect on the association between the rCThCN and %CThDiff than the 
amyloid positive subjects. 
Regions such as the ERC and the temporal pole had CTh which were between 3.3 and 
4mm in the CN stage and this CTh was reduced by 12% to 24% in the AD stage; whereas 
regions such as the pericalcarine region and the postcentral gyrus had CTh which were 
between 1.5 to 2 mm in the CN stage and were reduced by 0 to 5% in the AD stage 
(Table 21, Table 22, and Fig 21). These findings suggest that greater CTh in the CN stage 
may be a potential marker of greater vulnerability to the subsequent neurodegeneration 
due to AD.  
These findings initially appear divergent with a study by Sabuncu et al. on the ADNI 
population, which examined the association of a polygenic risk score to CTh in CN 
subjects and showed that a higher polygenic risk score was associated with decreased 
CTh among seven AD vulnerable regions [154]. However, a further examination of the 
associations between the polygenic risk score and CTh in individual studied regions, 
showed that among these seven regions, the region which is most vulnerable to 
neurodegeneration (23.78% thinning from CN to AD for E4+ in our sample) (Table 21), 
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namely the ERC, which has the greatest CTh among the seven region, showed no 
association to the polygenic risk score. In contrast, the posterior cingulate region, which 
was the only individual region showing a significant association between CTh and the 
polygenic risk score, was the least vulnerable of the seven regions to neurodegeneration 
(%CThDiff  = 2.5% for E4+) and had the least CTh (Table 21). As such, the results of the 
study by Sabuncu et al are not inconsistent with the notion that greater CTh in the CN 
stage is associated with greater vulnerability to neurodegeneration.  
The medial temporal lobe regions, including the ERC and parahippocampal gyrus receive 
highly processed input from every sensory modality, as well as input relating to ongoing 
cognitive processes. This information remains at least partially segregated among the 
different sensory visual, auditory olfactory, gustatory and tactile information from the 
neocortex and distribute it in a coded fashion to the hippocampus. The superficial layers 
of the ERC project to the dentate gyrus and hippocampus, with Layer II projecting 
primarily to the dentate gyrus and hippocampal region CA3, and layer III projecting 
primarily to hippocampal region CA1 and the subiculum. Spatially sensitive cells in layer 
II of the ERC have a crucial role in many spatially complex operations, including 
navigation and judging speed and accuracy of movements [155-159].  
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Fig. 22. Plot of rSUVRCN and %CThDiff with the estimated linear regression model for the E4+ and E4- 
groups. R is the correlation coefficient for the Pearson correlation, R_PPC is the correlation coefficient for 
the Pearson Partial Correlation, correcting for the rCThCN. Only ROIs in the left hemisphere were labeled, 
since results were similar for the left and the right hemisphere. Abbreviations: bankssts, banks of the 
superior temporal sulcus; CAC, caudal anterior cingulate; CMF, caudal middle frontal; ERC, entorhinal 
cortex; IP, inferior parietal; IT, inferior temporal; IC, isthmus cingulate; LO, lateral occipital; LOF, lateral 
orbitofrontal; MOF, medial orbitofrontal; MT, middle temporal; PHG, parahippocampal; POP, pars 
opercularis; POB, pars orbitalis; PTG, pars triangularis; PC, posterior cingulate; RAC, rostral anterior 
cingulate; RMF, rostral middle frontal; SF, superior frontal; SP, superior parietal; ST, superior temporal; 
SM, supramarginal; FP, frontal pole; TP, temporal pole; TT, transverse temporal. 
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Fig. 23. Plot of rCThCN and %CThDiff with the estimated linear regression model for the global amyloid 
positive (gSUVR+) and negative (gSUVR-) groups. R is the correlation coefficient for the Pearson 
correlation; R_PPC is the correlation coefficient for the Pearson Partial Correlation, adjusting for 
rSUVRCN. Only ROIs in the left hemisphere were labeled. Abbreviations: bankssts, banks of the superior 
temporal sulcus; CAC, caudal anterior cingulate; CMF, caudal middle frontal; ERC, entorhinal cortex; IP, 
inferior parietal; IT, inferior temporal; IC, isthmus cingulate; LO, lateral occipital; LOF, lateral 
orbitofrontal; MOF, medial orbitofrontal; MT, middle temporal; PHG, parahippocampal; POP, pars 
opercularis; POB, pars orbitalis; PTG, pars triangularis; PC, posterior cingulate; RAC, rostral anterior 
cingulate; RMF, rostral middle frontal; SF, superior frontal; SP, superior parietal; ST, superior temporal; 
SM, supramarginal; FP, frontal pole; TP, temporal pole; TT, transverse temporal. 
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Greater CTh in the ERC and perirhinal cortex most likely represents the greater number 
of neurons, synapses and complexity of operations which are routinely performed by 
these brain regions [160]. Dickerson et al. showed that greater CTh in medial temporal 
regions was associated with better performance on verbal memory tasks and greater 
activation in these regions on functional MRI scans, in elderly CN subjects [161]. 
Progression of neurodegenerative pathology appears to occur preferentially in brain 
regions with the greatest connectivity and trafficking. For example, Seeley et al. have 
shown a direct link between intrinsic connectivity and gray matter structure across 
healthy individuals and have described nodes within each functional network which 
“exhibited tightly correlated gray matter volumes”. They concluded that their findings 
suggest that “human neural networks can be defined by synchronous baseline activity, 
and selective vulnerability to neurodegenerative illness” [162]. The aggregation of 
misfolded disease proteins arises inside small, selectively vulnerable neuron populations 
in certain brain regions [163-165] and, as evidenced in human spongiform 
encephalopathies, conformational changes in misfolded prion protein results in disease 
propagation along the most active transsynaptic connections [166]. Neuropathological 
[11], neuroimaging [167, 168], and transgenic animal models [169], all suggest that 
neurodegeneration may relate to neural network dysfunction [168, 170], and selective 
vulnerability of specific brain regions may represent their status as hubs in very active 
networks.   
In this study we have also shown that regions, such as the ERC, which show the greatest 
propensity for neurodegeneration has the lowest regional Aβ load, whereas many regions 
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with relatively high Aβ deposition, show the lowest propensity for atrophy. Although 
using multiple regression analyses, Aβ burden was found to have a significant effect on 
neurodegeneration [80], this effect was much smaller in comparison to the association of 
CTh in the CN stage with neurodegeneration. Specifically, the most AD prone regions, 
such as ERC, parahippocampal, and temporal pole [129-132], had the greatest atrophy 
and the greatest baseline CTh, but the least Aβ load. Conversely, other AD vulnerable 
regions, such as posterior cingulate, precuneus, inferior parietal, and isthmus cingulate, 
experienced lower atrophy but the Aβ burden in these regions was higher. This 
discrepancy between regional Aβ deposition and regional reduction of CTh in patients 
with AD has been described previously [171]. These findings are consistent with the 
prevailing view that Aβ deposition initiates or acts as a catalyst for the neurodegenerative 
process but that the correlation of such process with tau-protein deposition and tau 
associated neurofibrillary tangles concentration is much stronger than that with Aβ 
deposition [172]. 
In addition, the significant association of larger rCThCN and greater atrophy after ruling 
out the effect of regional Aβ burden agrees with the findings in a previous study [136], 
which may add credence to the belief that Aβ does not play a leading role in brain 
atrophy [172]. Instead, tau pathology, inflammation, or disturbance in axonal transport 
processes may contribute to the ongoing neurodegeneration. However, the impact of 
APOE4 carrier status on neurodegeneration was not significant in comparison to the risk 
associated with regional CTh. Both the E4+ and E4- subjects showed a strong association 
between CTh in the CN stage and the propensity for neurodegeneration (Fig 21). 
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The main weakness of this study is that it is a cross-sectional analysis. Unfortunately, in 
the ADNI cohort it is unlikely that a sufficient number of CN individuals will progress to 
AD dementia to actually relate original cortical thickness to rate of neurodegenerative 
regions in AD-related areas longitudinally, especially when accounting for the APOE4 
carrier status and the availability of AV45 PET scans corresponding to the original MRI.  
Longitudinal studies conducted on clinically normal individuals who have progressed to 
AD or were Aβ positive at baseline, have shown that mean CTh of AD vulnerable regions 
at baseline are thinner in comparison to the same regions among individuals who did not 
progress to AD, or were Aβ negative at baseline. However, unlike the current 
investigation, these studies do not directly address the important question of whether CTh 
among individual regions is related to vulnerability to neurodegeneration [79, 173]. The 
main strength of this cross-sectional study is the availability of Aβ biomarkers and APOE 
genotypes in this ADNI cohort, which allow various factors to be assessed in this analysis 
of selective vulnerability. Besides, considering that aging and AD might have 
overlapping effects on the atrophy in specific cortical regions [174, 175], the study based 
on the age equivalent CN and AD groups superimposed the AD-specific changes to the 
age related progressive atrophy.  
7.5. Conclusion 
In retrospect, in the present study, there is evidence for a strong positive association 
between rCThCN and the severity of neurodegeneration (%CThDiff) in all brain regions. 
While we do not have an explanation for the most selective vulnerability for 
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neurodegeneration of brain regions having the greatest CTh in the CN stage, we propose 
that, among other factors, greater CTh is associated with higher synaptic density, greater 
connectivity and complexity of function, which are factors that have been associated with 
a greater propensity to neurodegeneration. Other factors, such as disturbance in axonal 
transport, or inflammatory processes, in the presence of plaques and neurofibrillary 
tangles may also play a role in mediating the interaction between greater CTh, greater 
connectivity and complexity of function and propensity for neurodegeneration. Our 
finding also show that regional Aβ load has a comparatively small but significant impact, 
but that APOE4 genotype and global Aβ load had no significant impact on the propensity 
for neurodegeneration.  
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